Maintaining GDMT while lowering potassium in heart failure
10' education - Mar. 27, 2023 - Javed Butler, MD, Ileana L. Piña, MD, and Patrick Rossignol, MD, PhD
A wearable device using infrared spectrophotometry to detect troponin I
3' education - Mar. 27, 2023 - Prof. Partho Sengupta, MD
Do personalized reminders to clinicians result in higher use of high-intensity statins?
3' education - Mar. 23, 2023 - Prof. Salim Virani, MD, PhD
A call to action: optimizing treatment in CKD
10' education - Mar. 22, 2023 - Prof. Meg Jardine, MD, PhD
Initiating PCSK9 mAb after ACS: When and how to start?
10' education - Mar. 22, 2023 - Prof. Wouter Jukema, MD, PhD and Prof. Pasquale Perrone-Filardi, MD, PhD
Interesting developments in the field of PCSK9 inhibition
3' education - Mar. 21, 2023 - Prof. Deepak Bhatt, MD
Implementing precision health for public health using causal AI
3' education - Mar. 21, 2023 - Ami Bhatt, MD
Causal AI can substantially improve the value of polygenic risk score for CVD
3' education - Mar. 21, 2023 - Prof. Brian Ference, MD
Well-designed EHR tools can improve prescribing of MRA in HFrEF
3' education - Mar. 21, 2023 - Amrita Mukhopadhyay, MD
Timing of benefits of intentional weight loss in cardiometabolic disease
5' education - Mar. 20, 2023 - Naveed Sattar, MD, PhD
Findings of a phase 2 trial with aldosteron synthase inhibitor in hypertension
3' education - Mar. 8, 2023 - Prof. Deepak Bhatt, MD
Promising results for oral PCSK9i to proceed to phase 3 trials
3' education - Mar. 8, 2023 - Prof. Christie Ballantyne, MD
Benefit and safety profile of icosapent ethyl in patients with recent ACS
3' education - Mar. 7, 2023 - Prof. Gabriel Steg, MD
Residual inflammatory risk is major driver of CV events and mortality in statin-treated patients
3' education - Mar. 7, 2023 - Prof. Paul Ridker, MD
Early eGFR decline after transitioning to ARNI not associated with adverse outcomes
3' education - Mar. 6, 2023 - Safia Chatur, MD
New evidence-based non-statin treatment to lower LDL-c and CV risk
3' education - Mar. 6, 2023 - Prof. Peter Libby, MD
Assocation between low-carbohydrate high-fat diet and MACE
3' education - Mar. 6, 2023 - Liam Brunham, MD, PhD
Where is bempedoic acid going to fit in?
3' education - Mar. 6, 2023 - Prof. Kausik Ray, MD
Strengths and limitations of phase 3 trial with bempedoic acid
3' education - Mar. 5, 2023 - Prof. Eugene Yang, MD
Protective cardiac effects of statin in patients with lymphoma treated with anthracyclines
3' education - Mar. 5, 2023 - Prof. Marielle Scherrer-Crosbie, MD, PhD
Results of CV outcomes trial with bempedoic acid in statin-intolerant patients
3' education - Mar. 5, 2023 - Prof. Steven Nissen, MD
One-year results of transcatheter tricuspid valve edge-to-edge repair for tricuspid regurgitation
3' education - Mar. 5, 2023 - Kendra Grubb, MD
Revascularization in cardiac surgery
10' education - Feb. 28, 2023 - Lauren Barron, MD, Navin Kapur, MD, Adam DeVore, MD
An urgent call for action to tackle excess adiposity
5' education - Feb. 28, 2023 - Prof. Naveed Sattar, MD, PhD
Revascularization in high-risk PCI patients
10' education - Feb. 28, 2023 - Navin Kapur, MD, Adam DeVore, MD, Lauren Barron, MD,
Care gap in assessing CAD
10' education - Feb. 16, 2023 - Adam DeVore, MD, Lauren Barron, MD, Navin Kapur, MD
When and how to initiate SGLT2i in CKD
10' education - Feb. 14, 2023 - Prof. David Wheeler, MD
What is the evidence of SGLT2i in CKD?
10' education - Feb. 7, 2023 - Prof. Hiddo L. Heerspink, PhD
Guidance for an individualized statin intolerance approach
5' education - Jan. 30, 2023 - Prof. Maciej Banach, MD, PhD
Treating iron deficiency in patients with HFrEF: A review of the recent data for IV iron replacement therapy
10' education - Jan. 5, 2023 - Prof. Javed Butler, MD, Prof. Stefan Anker, MD, PhD, Piotr Ponikowski, MD, PhD, and Robert J. Mentz, MD
Inflammation as a new target in CV risk reduction
10' education - Dec. 13, 2022 - Prof. Paul Ridker, MD
Findings of a trial with pemafibrate in a contemporary patient population
5' education - Dec. 7, 2022 - Prof. Paul Ridker, MD
Tackling risk reduction in ASCVD: A clinical case
10' education - Dec. 5, 2022 - Prof. Lawrence Leiter, MD
Mechanistic clues to understanding the benefits of icosapent ethyl
10' education - Nov. 28, 2022 - Prof. Matthew Budoff, MD
Long-term efficacy and safety of intravenous iron in HF
3' education - Nov. 21, 2022 - Paul R. Kalra
Applying GDMT for iron deficiency in heart failure
10' education - Nov. 17, 2022 - Prof. Piotr Ponikowski, MD, PhD, Adrian F. Hernandez, MD, Prof. Andrew Sindone, MD
Maximally tolerated or suboptimal therapy? Clinical perspectives on rechallenging RAASi therapy
10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD & Prof. Patrick Rossignol, MD, PhD
Identifying and treating iron deficiency in heart failure
10' education - Nov. 17, 2022 - Robert J. Mentz, MD & Prof. Peter van der Meer, MD, PhD
Optimizing GDMT in HFrEF and management of hyperkalemia
10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD
Why ischemia matters when it comes to iron deficiency in heart failure
10' education - Nov. 17, 2022 - Prof. Marco Metra, MD & Prof. Piotr Ponikowski, MD, PhD
How to choose the optimal therapy?
10' education - Nov. 17, 2022 - Prof. Kausik Ray, MD
The role of potassium binders in optimal HF management: Discussing the DIAMOND study
10' education - Nov. 17, 2022 - Prof. Ileana L. Piña, MD, Prof. Stefan D. Anker, MD, PhD, Prof. Javed Butler, MD, Prof. Bertram Pitt, MD
New perspectives in managing heart failure and hyperkalemia - The cardiorenal angle
10' education - Nov. 17, 2022 - Prof. Mikhail Kosiborod, MD & Prof. Austin G. Stack, MD
Addressing late-breaking data on triglycerides, fibrates and omega-3FAs
15' education - Nov. 16, 2022 - Prof. Peter Libby, MD, Prof. Gabriel Steg, MD, Prof. Kausik Ray, MD
Reducing morbidity and mortality in patients with CKD and T2DM
10' education - Nov. 14, 2022 - Pam Taub, MD, Prof. George Bakris, MD, and Prof. Gerasimos Filippatos, MD
A new option for cardiorenal protection for patients with CKD and T2DM
10' education - Nov. 14, 2022 - Prof. Gerasimos S. Filippatos, MD, Javier Morales, MD, and Angela Yee-Moon Wang, MD, PhD
Effects of a guideline-based approach on achieving LDL-c goals
3' education - Nov. 14, 2022 - Aaram Omar Khader, MD
LDL-c: new insights into its role as causal risk factor and target for therapy
10' education - Nov. 11, 2022 - Prof. Brian Ference, MD
Improved outcomes with rapid uptitration of HF medication after acute HF
3' education - Nov. 8, 2022 - Prof. Alexandre Mebazaa, MD, PhD
Low-dose statin lowers LDL-c more than dietary supplements
3' education - Nov. 8, 2022 - Luke J. Laffin, MD
Dramatic reduction in primary endpoint with precision testing in stable patients with suspected CAD
3' education - Nov. 7, 2022 - Prof. Pamela Douglas, MD
Is one diuretic better than the other diuretic in veterans with hypertension?
3' education - Nov. 7, 2022 - Areef Ishani, MD
Head-to-head comparison of two loop diuretics in patients hospitalized with HF
3' education - Nov. 7, 2022 - Robert J. Mentz, MD
Mindfulness-based BP-reduction program outperforms enhanced usual care
3' education - Nov. 7, 2022 - Eric Loucks, PhD
Composite endpoint of CV death or kidney disease worsening reduced by SGLT2i in CKD
3' education - Nov. 7, 2022 - David Preiss, PhD
Gene editing to treat transthyretin amyloidosis with cardiomyopathy
3' education - Nov. 6, 2022 - Kiran Musunuru, MD, PhD
First-in-human study with CRISPR/Cas9-based gene editing in ATTR amyloid cardiomyopathy
3' education - Nov. 6, 2022 - Prof. Julian D. Gillmore, MD, PhD
Addressing the unmet needs in LDL-c lowering; what can we expect?
10' education - Nov. 4, 2022 - Prof. John Kastelein, MD, PhD
11 Practical implications of REDUCE-IT
10' education - Oct. 28, 2022 - Prof. Subodh Verma, MD, PhD
Identification and management of patients with HFpEF and diabetes
10' education - Oct. 26, 2022 - Prof. Silvio Inzucchi, MD & Prof. Pardeep Jhund, MD, PhD
Women in cardiology research
5' education - Oct. 26, 2022 - Biljana Parapid, MD, PhD
HFpEF and diabetes: What are the clinical challenges?
10' education - Oct. 25, 2022 - Prof. Pardeep Jhund, MD, PhD
SGLT2i in HFmrEF and HFpEF across the spectrum of glycemia
10' education - Oct. 24, 2022 - Prof. Silvio Inzucchi, MD
Effects of intensive lipid lowering on coronary plaque characteristics
10' education - Oct. 24, 2022 - Prof. Lorenz Räber, MD, PhD & Prof. Stephen Nicholls, MD
The spectrum of therapeutic options: which therapies to consider?
10' education - Oct. 18, 2022 - Prof. Ulf Landmesser, MD
CODE-EHR, a framework for the use of EHR data in clinical research
5' education - Oct. 13, 2022 - Prof. Folkert Asselbergs, MD, PhD
Practical guidance on use of potassium binders in the management of hyperkalemia in heart failure
10' education - Oct. 12, 2022 - Clara Bonanad Lozano, MD, PhD
Targeting Lp(a): therapeutic insights and novel developments
10' education - Oct. 12, 2022 - Prof. Erik Stroes, MD, PhD
Real-world evidence with PCSK9i mAb; implications and lessons for current clinical use
10' education - Oct. 12, 2022 - Raul Santos, MD, PhD & Prof. Maciej Banach, MD, PhD
Autoimmune diseases and risk of CVD
5' education - Oct. 12, 2022 - Prof. Naveed Sattar, MD, PhD
Is class I recommendation for aspirin use in CVD prevention too strong?
5' education - Oct. 12, 2022 - Prof. John Cleland, MD, PhD
A continuum of multifactorial benefits of icosapent ethyl?
10' education - Oct. 11, 2022 - Prof. Magnus Bäck, MD, PhD
How potassium binders can enable RAASi therapy in heart failure
10' education - Oct. 11, 2022 - Prof. Mikhail Kosiborod, MD
Lp(a) as independent causal risk factor: why should we focus on testing?
10' education - Oct. 11, 2022 - Prof. Florian Kronenberg, MD, PhD
The clinical challenge: a patient with multiple risk factors
10' education - Oct. 7, 2022 - Prof. Erik Stroes, MD, PhD
Targeting Lp(a) in CV risk reduction: where are we now?
10' education - Oct. 5, 2022 - Pia Kamstrup, MD, PhD
The importance of optimal RAASi therapy in heart failure
10' education - Oct. 5, 2022 - Prof. Dan Atar, MD
Targeting the PCSK9 pathway: where do novel therapies fit in?
10' education - Oct. 5, 2022 - Ann Marie Navar, MD, PhD
Sex-specific differences in the effects of LDL-c on CVD risk
5' education - Oct. 5, 2022 - Arjen Cupido, MD
Recent clinical insights into icosapent ethyl
10' education - Oct. 3, 2022 - Prof. Deepak Bhatt, MD
LDL-c lowering with CETP inhibitor in patients on high intensity statins
10' education - Oct. 3, 2022 - Prof. Kausik Ray, MD
Managing patients with hypertrophic cardiomyopathy: what is the therapeutic landscape?
10' education - Sep. 30, 2022 - Prof. Iacopo Olivotto, MD
2022 ADA/EASD consensus report on management of hyperglycemia in T2DM
3' education - Sep. 29, 2022 - Prof. John Buse, MD, PhD
Changing paradigms in LDL-c reduction
10' education - Sep. 28, 2022 - Prof. Kausik Ray, MD
Hypertrophic cardiomyopathy: making the diagnosis
10' education - Sep. 28, 2022 - Michelle Michels, MD, PhD
Unhiding hypertrophic cardiomyopathy, a call for action
10' education - Sep. 28, 2022 - Antonis Pantazis, MD
SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status
3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD
Greater intake of sodium and protein may predispose to deeper fall in GFR after start of SGLT2i
3' education - Sep. 21, 2022 - Marta Seghieri, MD
Consistent beneficial effect with GLP-1RA across broad range of kidney function and kidney damage
3' education - Sep. 21, 2022 - Prof. Peter Rossing, MD
Unexpected findings when comparing DOAC with VKA in rheumatic AF
3' education - Sep. 15, 2022 - Prof. Ganesan Karthikeyan, MD
Understanding the effects of ARNI in acute MI
3' education - Sep. 15, 2022 - Otavio Berwanger, MD, PhD
What have we learned from previous CETP inhibitor outcome trials?
10' education - Sep. 15, 2022 - Prof. Stephen Nicholls, MD
Meta-analysis on effects of statins on muscle symptoms
3' education - Sep. 12, 2022 - Prof. Colin Baigent, MD
Finding a place for fish oil in CVD prevention
10' education - Sep. 7, 2022 - Prof. Chris Packard, PhD
Aspirin or P2Y12i monotherapy for secondary prevention in patients with CAD?
3' education - Sep. 5, 2022 - Prof. Marco Valgimigli, MD, PhD
Phenotypic changes associated with aortic stenosis detected by AI-algorithm
3' education - Sep. 5, 2022 - Prof. Geoffrey Strange, MD, PhD
Increased coronary atherosclerotic plaque activity is associated with all-cause mortality
3' education - Sep. 5, 2022 - Prof. David Newby, PhD
Challenging results in trial evaluating PCI in severe ischemic LV dysfunction
3' education - Aug. 30, 2022 - Prof. Divaka Perera, MD
Long-term use of PCSK9i reduces CV events, including CV death
3' education - Aug. 29, 2022 - Michelle O'Donoghue, MD
FXIa inhibition in non-cardioembolic stroke patients
3' education - Aug. 29, 2022 - Ashkan Shoamanesh, MD
Screening using a smartphone-app more than doubles detection rate of AF
3' education - Aug. 28, 2022 - Prof. Axel Bauer, MD
A community-based screening trial for CVD with cardiac CT scan
3' education - Aug. 28, 2022 - Prof. Axel Diederichsen, MD
SGLT2i improves outcomes in HFpEF and HFmrEF
3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD
Combination therapy with loop diuretic and acetazolamide improves decongestion in acute HF
3' education - Aug. 27, 2022 - Prof. Wilfried Mullens, MD, PhD
Totality of evidence of SGLT2 inhibition in HF
3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD
All patients with HF regardless of EF benefit from SGLT2i
3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD
Prediction of life expectancy and life years gained by medication in HFrEF
3' education - Aug. 27, 2022 - Stefan Koudstaal, MD, PhD
Cognitive function not affected by ARNI
3' education - Aug. 26, 2022 - Prof. John McMurray, MD
A polypill for secondary prevention in post-MI patients
3' education - Aug. 26, 2022 - Valentin Fuster, MD, PhD
Lessons from the biology of CETP inhibition
10' education - Aug. 2, 2022 - Prof. John Kastelein, MD, PhD
Key innovations in lipid treatment
5' education - Aug. 2, 2022 - Prof. Chris Packard, PhD
Novel LDL-c lowering therapies: What is the potential for ANGPTL3 inhibition in HoFH?
10' education - July 25, 2022 - Prof. Frederick Raal, MD, PhD
Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options
10' education - July 21, 2022
Expanding evidence on SGLT2i: Where are we now and what can we expect?
10' education - July 21, 2022 - Prof. Scott Solomon, MD
Triglycerides most commonly a marker of ectopic fat accumulation
5' education - July 20, 2022 - Prof. Naveed Sattar, MD, PhD
Discussion - Clinical dilemmas in heart failure: Weighing the balance of RAASi and hyperkalaemia
10' education - July 20, 2022 - Prof. Andrew Coats, MD, Clara Bonanad Lozano, MD, PhD, and Aaron Wong, MD
Potassium binding as RAASi enabling therapy: applying recent insights into practice
10' education - July 18, 2022 - Aaron Wong, MD
Optimizing treatment for patients with HoFH
10' education - July 13, 2022 - Prof. Erik Stroes, MD, PhD
Primary care as gatekeeper in CKD and the need for collaboration with nephrologists
10' education - July 13, 2022 - Prof. Kamlesh Khunti, MD, PhD
Hyperkalemia in heart failure: Why should we care?
10' education - July 12, 2022 - Clara Bonanad Lozano, MD, PhD
Discussion - Rethinking the role of nephrologists in prevention of CKD - The opportunity of early risk identification
10' education - July 6, 2022 - Prof. Christoph Wanner, MD, Rikke Borg, MD, PhD, and prof. Kamlesh Khunti, MD, PhD
Discussion - Preventing CKD in patients with diabetes - Exploring the current and future role of GLP-1RA
10' education - July 6, 2022 - Prof. Johannes Mann, MD, prof. Filip Knop, MD, PhD, and prof. Katherine Tuttle, MD
Why is early screening and risk identification of CKD in diabetes important?
10' education - July 6, 2022 - Rikke Borg, MD, PhD
Clinical dialogue: Lowering ASCVD risk in a patient with T2DM and obesity
15' education - July 5, 2022 - Prof. Nikolaus Marx, MD and Adie Viljoen, MD
Benefits and evolving insights on SGLT2i in the spectrum of LVEF
10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD
HoFH: Why is early diagnosis important?
10' education - June 29, 2022 - Prof. Kausik Ray, MD
Barriers for preventing CKD in patients with diabetes
10' education - June 28, 2022 - Prof. Christoph Wanner, MD
Clinical dialogue: CV risk in diabetes
15' education - June 22, 2022 - Prof. Nikolaus Marx, MD and Michael Lehrke, MD
Guidelines, RAASi and hyperkalemia: the clinical dilemmas in heart failure
10' education - June 21, 2022 - Prof. Andrew Coats, MD
The clinical challenges of initiating guideline recommended therapy in HF
10' education - June 21, 2022 - Prof. John McMurray, MD
Distinct pathophysiological pathways in women and men with heart failure
5' education - June 16, 2022 - Alice Ravera, MD
No role of Lp(a) in thrombosis
3' education - June 16, 2022 - Prof. Alberico Catapano, PhD
Findings of analysis on pediatric FH patients in large global registry
3' education - June 16, 2022 - Kanika Dharmayat
Phenotyping HF with a supranormal ejection fraction
5' education - June 15, 2022 - Bart van Essen, MD
An increase in galectin-3 identifies males at risk of new-onset HF and new-onset cancer
5' education - June 15, 2022 - Freek van den Berg, MD
Ciculating ketonse bodies in acute HF treated with SGLT2i
5' education - June 14, 2022 - Suzanne Voorrips, MD
Genetic penetrance in cardiomyopathy
5' education - June 14, 2022 - Remco de Brouwer, MD
Need to restart and catch up in CVD prevention in time of COVID-19
10' education - June 13, 2022 - Prof. Richard Hobbs, MD
Which patients with CKD and diabetes will benefit from management with GLP-1RA?
10' education - June 13, 2022 - Prof. Katherine Tuttle, MD
What is relevant for nephrology with regard to GLP-1RA in CVD?
10' education - June 10, 2022 - Prof. Filip Knop, MD, PhD
How to overcome the excess ASCVD risk conferred by Lp(a)?
3' education - June 1, 2022 - Prof. Alberico Catapano, PhD
GLP-1RA as new treatment option on the horizon for obesity
3' education - May 31, 2022 - Prof. Ulrich Laufs, MD, PhD
Wake-up call to shift focus from treating CVD to preserving CV health
3' education - May 31, 2022 - Prof. Lale Tokgözoğlu, MD
New insights and guidelines for the management of CKD and diabetes
10' education - May 31, 2022 - Prof. Johannes Mann, MD
Targeting the ANGPTL3 pathway for lowering TG-rich lipoproteins
3' education - May 24, 2022 - Nicholas Marston, MD
What is the role of imaging and how can it guide medical therapy in ASCVD?
3' education - May 24, 2022 - Prof. Stephen Nicholls, MD
Welcome to the EAS 2022 congress
3' education - May 24, 2022 - Prof. Kausik Ray, MD
New oral therapy of CETP inhibition for lipid lowering
3' education - May 24, 2022 - Prof. Kausik Ray, MD
Need for a stratified approach to improve treatment of IHD
3' education - May 24, 2022 - Prof. Filippo Crea, MD
Management of cancer-associated VTE
10' education - May 12, 2022 - Prof. Stavros Konstantinides, MD
Emerging therapies in HCM: The potential role of cardiac myosin inhibitors
10' education - May 4, 2022 - Ahmad Masri, MD and prof. Deepak Bhatt, MD
Potential mechanisms of benefit of icosapent ethyl
10' education - May 3, 2022 - Prof. Chris Packard, PhD
Optimizing oral anticoagulation management for patients with AF
10' education - May 3, 2022 - Prof. Robert Storey, MD
The journey from hypothesis to reality on inflammation in CVD
10' education - Apr. 28, 2022 - Prof. Peter Libby, MD and prof. Paul Ridker, MD
Lipid management and the potential role of bempedoic acid
10' education - Apr. 26, 2022 - Rens Reeskamp, MD, PhD
Discussion - CV risk reduction beyond statin therapy: Exploring the role of Icosapent ethyl
10' education - Apr. 21, 2022 - Prof. Ulrich Laufs, MD, PhD, prof. Chris Packard, PhD and prof. Wouter Jukema, MD, PhD
Exploring the role of icosapent ethyl based on current clinical evidence
10' education - Apr. 21, 2022 - Prof. Wouter Jukema, MD, PhD
IL-6 as therapeutic target in inflammation and CVD
10' education - Apr. 21, 2022 - Prof. Paul Ridker, MD
Long-term efficacy and safety of radiofrequency renal denervation
5' education - Apr. 20, 2022 - Felix Mahfoud, MD
Hemodynamic valve deterioration in transcatheter aortic valves vs. surgical aortic valves
3' education - Apr. 20, 2022 - Megan Coylewright, MD
MI risk is best captured by number of apoB-containing lipoproteins
5' education - Apr. 20, 2022 - Nicolas Marston, MD
A positive view on a negative trial with DOAC after TAVR
3' education - Apr. 19, 2022 - Megan Coylewright, MD
Novel form of CV research with dietary education in the grocery store
3' education - Apr. 13, 2022 - Prof. Eileen Handberg, PhD
EHR-based intervention improves quality care for patients with HF
3' education - Apr. 13, 2022 - Tariq Ahmad, MD
Residual CV risk in patients on statin therapy
10' education - Apr. 13, 2022 - Prof. Alberto Zambon, MD, PhD
A first clinical trial testing the use of an H₂S donor after heart attack
5' education - Apr. 12, 2022 - Marie-Sophie de Koning, MD
Reductions in LVOT gradients, NYHA class and NT-proBNP with cardiac myosin inhibitor in HCM
5' education - Apr. 11, 2022 - Florian Rader, MD
Inflammation and anti-inflammatory therapy in CVD
10' education - Apr. 11, 2022 - Prof. Thomas Lüscher, MD
Study with ASO targeting ANGPTL3 mRNA highlights importance of rigorous evaluation of new therapies
3' education - Apr. 6, 2022 - Brian Bergmark, MD
PCSK9i reduces plaque burden in coronary arteries
3' education - Apr. 6, 2022 - Prof. Lorenz Räber, MD, PhD
Beginning of an era: Treatment of elevated Lp(a)
3' education - Apr. 6, 2022 - Steven Nissen, MD
Atrial fibrillation: From risk prediction to clinical outcomes
10' education - Apr. 6, 2022 - Prof. Stefan Hohnloser, MD
Reduction of bleeding with tranexamic acid after noncardiac surgery
3' education - Apr. 5, 2022 - Edward Fry, MD
Cardiac myosin inhibitor sustainably reduces LVOT gradient in HCM
3' education - Apr. 4, 2022 - Maya Guglin, MD, PhD
Optimization of RAASi and low risk of hyperkalemia with potassium binder in HFrEF
3' education - Apr. 4, 2022 - Prof. Javed Butler, MD
Updates in the new AHA/ACC/HFSA heart failure guideline
3' education - Apr. 3, 2022 - Prof. Paul Heidenreich, MD
Does adding salt to an egg harm HF patients?
3' education - Apr. 3, 2022 - Joseph Cleveland, MD
Treatment of chronic hypertension reduces adverse pregnancy outcomes
3' education - Apr. 3, 2022 - Prof. Alan Tita, MD, PhD
Impact of new first-in-class medical therapy in obstructive HCM
3' education - Apr. 3, 2022 - Joseph Cleveland, MD
Study on effects of low-sodium diet on clinical events in HF
3' education - Apr. 2, 2022 - Prof. Justin Ezekowitz
Cardiac myosin inhibitor reduces need for septal reduction therapy in obstructive HCM
3' education - Apr. 2, 2022 - Prof. Milind Desai, MD
3 Challenges when targeting inflammation in residual CV risk
10' education - Mar. 29, 2022 - Prof. Filippo Crea, MD
Immunity and inflammation in atherosclerosis - no longer just a theory
10' education - Mar. 29, 2022 - Prof. Peter LIbby, MD
Wide distribution of CVD-free life-years gained with GLP-1RA
5' education - Mar. 21, 2022 - Jan Westerink, MD, PhD
Symposium: Omega-3 icosapent ethyl and stroke reduction in ASCVD
Lecture - Mar. 16, 2022 - Prof. Marc Alberts, MD, prof. Matthew Budoff, MD, prof. Lawrence Leiter, MD
What clinical data support the practical use of potassium binders?
10' education - Mar. 16, 2022 - Prof. Peter van der Meer, MD, PhD
The renal tamponade hypothesis
5' education - Mar. 15, 2022 - Eva Boorsma, MD
Mode of action of potassium binders
10' education - Mar. 1, 2022 - Joost Beusekamp, MD, PhD
Colchicine in coronary disease
5' education - Mar. 1, 2022 - Aernoud Fiolet, MD, PhD
Large global inequity in treatment and outcomes of HoFH
5' education - Feb. 16, 2022 - Tycho Tromp, MD
Which patients benefit from potassium binders?
10' education - Feb. 15, 2022 - Kevin Damman, MD, PhD
Prognostic value of epicardial adipose tissue in patients with HFmrEF and HFpEF
5' education - Feb. 1, 2022 - Gijs van Woerden, MD
Low-dose NOAC after COVID-19 hospitalization in patients with high thrombotic risk
3' education - Jan. 11, 2022 - Prof. Freek Verheugt, MD, PhD
Targeting triglyceride-rich remnant lipoproteins
10' education - Dec. 21, 2021 - Prof. Daniel Gaudet, MD, PhD
Working towards eradication of CV risk
10' education - Dec. 15, 2021 - Prof. Erik Stroes, MD, PhD
A recap of a study on reversal of the effect of P2Y12i
5' education - Dec. 14, 2021 - Prof. Deepak Bhatt, MD
Rethinking responsibilities in the prevention and management of cardiometabolic disease
10' education - Dec. 7, 2021 - Prof. Stephan Jacob, MD
FXIa inhibitor as a promising new anticoagulant drug
3' education - Nov. 23, 2021 - Prof. Jeffrey Weitz, MD
Why focus on triglyceride-rich lipoproteins and their remnants?
10' education - Nov. 23, 2021 - Prof. Henry Ginsberg, MD
Digital transformation in cardiovascular healthcare
3' education - Nov. 22, 2021 - Alexander J. Blood, MD
What is the effect of low-dose aspirin on dementia risk in T2DM?
3' education - Nov. 16, 2021 - Prof. Jane Armitage
No significant improvement of outcomes with EPA in COVID-19
3' education - Nov. 16, 2021 - Rafael Diaz, MD
Rigorous assessment of effect of individual triggers for AF
3' education - Nov. 15, 2021 - Prof. Gregory Marcus, MD
Screening for AF with irregular heart rhythm detection by Fitbit wearables
3' education - Nov. 14, 2021 - Steven Lubitz, MD
Randomized study on effects of coffee consumption on acute physiological changes
3' education - Nov. 14, 2021 - Prof. Gregory Marcus, MD
Ambitious project on use of non-physician providers to control BP
3' education - Nov. 14, 2021 - Prof. Keith Ferdinand, MD
What is the best timing for P2Y12i cessation prior to CABG in patients with ACS?
3' education - Nov. 13, 2021 - Derek So, MD
Panel discussion: Measuring inflammation in the coronary circulation
15' education - Nov. 9, 2021 - Prof. Peter Libby, MD, prof. John Deanfield, MD, and prof. Charalambos Antoniades, MD
Statin therapy in COVID-19 patients
5' education - Nov. 8, 2021 - Prof. Maciej Banach, PhD, MD
Integrating EPA-based therapy in the management of residual CV risk
10' education - Nov. 1, 2021 - Prof. Ph. Gabriel Steg, MD - Online CME
Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes
15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME
Dialogue on how to overcome clinical inertia with regard to SGLT2i
10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME
SGLT2i: Overview of recent trials and guideline recommendations
10' education - Oct. 28, 2021 - Prof. Nikolaus Marx, MD - Online CME
Introduction on tackling cardiorenal risk in diabetes
10' education - Oct. 28, 2021 - Prof. Melanie Davies, MD - Online CME
Lp(a) as therapeutic target - now and in the future
10' education - Oct. 28, 2021 - Prof. Erik Stroes, MD, PhD - Online CME
Therapeutic dose of heparin in COVID-19 - the jury is still out
5' education - Oct. 26, 2021 - Prof. Hugo ten Cate, MD, PhD
The clinical dilemma of RAASi therapy and hyperkalemia
10' education - Oct. 20, 2021 - Prof. Javed Butler, MD - Online CME
Detecting residual cardiovascular risk using coronary CT angiography
10' education - Oct. 18, 2021 - Prof. Charalambos Antoniades, MD, PhD
Triglyceride-rich lipoproteins and residual CV risk
10' education - Oct. 14, 2021 - Prof. Erik Stroes, MD, PhD
Time to previous ACS event has no effect on efficacy of colchicine
5' education - Oct. 14, 2021 - Tjerk Opstal, MD
What is the evidence of EPA-based therapy for CV prevention?
10' education - Oct. 12, 2021 - Prof. Lale Tokgözoğlu, MD - Online CME
Novel modulators of inflammation in atherosclerosis
10' education - Oct. 6, 2021 - Prof. Peter Libby, MD
RAASi as a fundamental pillar in HF
10' education - Oct. 4, 2021 - Prof. Andrew Coats, MD - Online CME
Expanding therapeutic options for LDL-c lowering
10' education - Oct. 1, 2021 - Prof. Christie Ballantyne, MD - Online CME
Understanding the increased CV risk of high Lp(a) levels
10' education - Sep. 28, 2021 - Prof. Florian Kronenberg, MD, PhD - Online CME
Combination therapy with PCSK9 mAbs in post-MI patients
10' education - Sep. 22, 2021 - Derek Connolly, MD, PhD - Online CME
Implementation of salt substitution strategies
3' education - Sep. 21, 2021 - Prof. Barbara Casadei, MD
Unravelling the triglyceride story
10' education - Sep. 21, 2021 - Prof. Peter Libby, MD - Online CME
Risks associated with hyperkalemia
10' education - Sep. 16, 2021 - Prof. Stefan Anker, MD, PhD - Online CME
NOAC as possible treatment option in patients with AF after successful TAVI
5' education - Sep. 13, 2021 - Prof. Nicolas van Mieghem, MD, PhD
Why focus on Lp(a)?
10' education - Sep. 13, 2021 - Prof. Naveed Sattar, MD, PhD - Online CME
Surgery vs. stenting with asymptomatic critical carotid artery stenosis
5' education - Sep. 7, 2021 - Prof. Freek Verheugt, MD, PhD
Changing the paradigm on LDL-c-lowering in high CV risk patients
10' education - Sep. 7, 2021 - Prof. Kausik Ray, MD - Online CME
Non-steroidal MRA effective in reducing CV events in patients with diabetes and CKD
5' education - Aug. 31, 2021 - Prof. Bertram Pitt, MD
Switching to a salt substitute reduces risk of stroke, CV events and death
5' education - Aug. 31, 2021 - Prof. Bruce Neal, MD, PhD
Moving the field of medicine and science is a collective exercise
3' education - Aug. 29, 2021 - Prof. Stephan Achenbach, MD, president ESC
SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events
3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD
Ground-breaking HF trial with evidence for SGLT2i at EF>40%
3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD
CV outcomes reduced by nonsteroidal MRA in patients with diabetes and CKD
3' education - Aug. 28, 2021 - Kevin Damman, MD, PhD
Kidney and HF outcomes with SGLT2i across EF spectrum in HF
3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD
What is new in the 2021 ESC HF guidelines regarding patients with EF>40%?
3' education - Aug. 27, 2021 - Prof. Carolyn Lam, MD, PhD
Exciting findings of a pooled analysis of two large HF trials with SGLT2i
3' education - Aug. 27, 2021 - Milton Packer, MD
Another chapter in the SGLT2i book
3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD
Phenotypic clusters in HFpEF
5' education - July 28, 2021 - Alicia Uijl, PhD
Where do GLP-1RA fit in in current and future management of CKD?
10' education - July 26, 2021 - Frederik Persson, MD - Online CME
Treatment goals for patients with T2DM and CKD
10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME
Continued benefit of statin treatment after stopping therapy
5' education - July 12, 2021 - Jackie Bosch, PhD
How can GLP-1RA benefit a patient with diabetes and CKD?
10' education - July 1, 2021 - Daniël van Raalte, MD, PhD - Online CME
Reviewing trials with P2Y12 blocker (mono)therapy after ACS
5' education - June 29, 2021 - Prof. Freek Verheugt, MD, PhD
Practical challenges with SGLT2i therapy in patients with T2DM and CKD
10' education - June 29, 2021 - Alice Cheng, MD - Online CME
Prevention strategies in patients with CKD and T2DM
10' education - June 24, 2021 - Ofri Mosenzon, MD - Online CME
Patient profiling in HFrEF to tailor therapy
5' education - June 21, 2021 - Pardeep Jhund, MD, PhD
Clinical inertia in CKD - What is the rationale for SGLT2i?
10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME
Kidney benefit by SGLT2i may be mediated by hematocrit
5' education - June 14, 2021 - Prof. Christoph Wanner, MD
Head-to-head comparison of risk scores for ischemic stroke in patients with AF and CKD
5' education - June 14, 2001 - Ype de Jong, MD
Statin therapy during pregnancy?
5' education - June 9, 2021 - Prof. Maciej Banach, PhD, MD
Can targeting of IL-6 lead to CV protection in CKD?
5' education - May 19, 2021 - Prof. Paul Ridker, MD
Renal denervation as option for patients with hypertension despite medications
5' education - May 18, 2021 - Prof. Ajay Kirtane, MD
A call to solve the controversy on omega-3FAs trials
5' education - May 17, 2021 - Prof. Eileen Handberg, PhD
No superiority with NOAC compared to standard care following TAVI
5' education - May 17, 2021 - Jean-Philippe Collet, MD, PhD
Possible substitution of aspirin by P2Y12 inhibitor monotherapy one year after PCI
5' education - May 16, 2021 - Prof. Freek Verheugt, MD
No difference in clinical outcomes with 81 mg vs. 325 mg aspirin in established CVD
5' education - May 16, 2021 - William Schuyler Jones, MD
12-Months follow up of rapid hs -TnT protocol in ACS suspected patients
5' education - May 16, 2021 - Prof. Derek Chew, MD, PhD
No definite difference for primary endpoint but proven safety with ARNI in MI patients
5' education - May 15, 2021 - Prof. Marc Pfeffer, MD, PhD
Prognostic value of natriuretic peptides in patients with HF and kidney dysfunction
10' education - May 11, 2021 - Prof. James Januzzi, MD
A novel simplified algorithm to achieve LDL-c goal in very-high risk patients
15' education - May 11, 2021 - Prof. Luis Masana, MD, PhD and prof. Erik Stroes, MD, PhD
A new approach with LLT for very-high and extremely-high risk patients
5' education - May 6, 2021 - Prof. Maciej Banach, PhD, MD
Lipid-lowering therapies for statin-intolerant patients
15' education - May 5, 2021 - Prof. Maciej Banach, MD, PhD and prof. Ulrich Laufs, MD, PhD
Treatment algorithms for HFpEF
10' education - May 4, 2021 - Prof. John Cleland, MD
Solutions for improving LDL-c goal attainment - changing treatment patterns
15' education - Apr. 28, 2021 - Prof. Ulrich Laufs, MD, PhD and Derek Connolly, MD, PhD - Online CME
Recommendations for treatment algorithm of HFrEF
10' education - Apr. 26, 2021 - Andrew Coats, MD
PCSK9 inhibition in clinical practice
5' education - Apr. 21, 2021 - Prof. Maciej Banach, PhD, MD
Solutions for improving LDL-c goal attainment - advances in patient selection
15' education - Apr. 20, 2021 - Prof. Maciej Banach, MD, PhD, and prof. John Kastelein, MD, PhD
What are current challenges and barriers in achieving LDL-c goals?
15' education - Apr. 13, 2021 - Prof. Lale Tokgözoğlu, MD and prof. Kausik Ray, MD - Online CME
Outcomes with P2Y12 inhibitors after PCI according to CYP2C19 genotype
5' education - Apr. 12, 2021 - Danny Claassens, MD
Novel strategy of triple therapy with bempedoic acid, ezetimibe and statin
5' education - Apr. 8, 2021 - Prof. Stephen Nicholls, MD
Effects of iron deficiency on outcomes in HF
10' education - Apr. 6, 2021 - Adrian F. Hernandez, MD
The gap between guideline LDL-c goals and current practice: How are we doing?
15' education - Apr. 1, 2021 - Prof. François Mach, MD and prof. Erik Stroes, MD, PhD - Online CME
Clinical outcomes with low dose vs. high dose DOAC in AF
5' education - Mar. 30, 2021 - Prof. Jan Steffel, MD
The proven case for LDL-c lowering
15' education - Mar. 26, 2021 - Prof. Kausik Ray, MD and prof. John Kastelein, MD, PhD
Concomitant use of diuretics and SGLT2i in HF
10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD
Personalized antithrombotic therapy after PCI
5' education - Mar. 17, 2021 - Niels van der Sangen, MD
Ketones as a possible therapeutic option for patients with CVD
10' education - Mar. 16, 2021 - B. Daan Westenbrink MD, PhD
GLP-1RA induces weight loss in adults with overweight or obesity
5' education - Mar. 2, 2021 - Prof. Robert Kushner, MD
Reduction in albuminuria predicts future benefits on CV and renal outcomes in T2DM
10' education - Feb. 22, 2021 - Frederik Persson, MD
Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF
10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD
Rise in ANP might mediate benefits of ARNI in HFrEF
10' education - Feb. 16, 2021 - Sean Murphy, MD
Anti-inflammation heralds the future of CV medicine
10' education - Feb. 8, 2021 - Prof. Paul Ridker, MD
No decrease in thrombotic complications in second COVID-19 wave
5' education - Feb. 4, 2021 - Fleur Kaptein, MD
Two medical therapies elevated to front line in 2021 update HF ECDP
5' education - Feb. 1, 2021 - Prof. James Januzzi, MD
SGLT2 inhibitor is kidney protective, even if eGFR <30
3' education - Jan. 26, 2021 - Prof. George Bakris, MD
Older adults should also be treated to lower LDL-c
5' education - Jan. 18, 2021 - Prof. Børge Nordestgaard, MD
Explained risk from apoB-containing lipoproteins to MI
5' education - Jan. 13, 2021 - Prof. Børge Nordestgaard, MD
GLP-1RAs: What are the future directions in development?
10' education - Jan. 6, 2021 - Prof. John Deanfield, MD - Online CME
Clinical outcome trial with IV iron in patients with iron deficiency, stabilized after acute HF
3' education - Dec. 15, 2020 - Prof. Peter van der Meer, MD, PhD
What is the clinical evidence for the benefits of GLP-1RAs?
10' education - Dec. 10, 2020 - Prof. Subodh Verma, MD - Online CME
Role of GLP-1RA in practice
10' education - Dec. 3, 2020 - Prof. Eduard Montanya, MD - Online CME
How do GLP-1RAs work?
10' education - Dec. 1, 2020 - Prof. Naveed Sattar, MD - Online CME
Newest ESC guidelines on diabetes and CVD
10' education - Nov. 24, 2020 - Prof. Francesco Cosentino, MD - Online CME
Update on COVID-19 at AHA Scientific Sessions
10' education - Nov. 24, 2020 - Anthony Fauci, MD
Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients
5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD
Ferric carboxymaltose in patients with iron deficiency after acute HF to reduce HF hospitalizations
5' education - Nov. 23, 2020 - Prof. Piotr Ponikowski, MD, PhD
Strengths and limitations of one-month DAPT trial
3' education - Nov. 19, 2020 - Róisín Colleran, MD
Comparing P2Y12 inhibitors in patients undergoing elective PCI
3' education - Nov. 19, 2020 - Jur ten Berg, MD, PhD
Which patients to consider for GLP-1RA?
10' education - Nov. 18, 2020 - Prof. Stephan Jacob, MD - Online CME
Results of omega-3 fatty acids trials may not be contradictory
3' education - Nov. 16, 2020 - Prof. Deepak Bhatt, MD
No effect of omega-3 carboxylic acid on MACE in high-risk patients
3' education - Nov. 16, 2020 - Prof. Michael Lincoff, MD
What is the value of a polypill with or without aspirin?
3' education - Nov. 16, 2020 - Prof. Salim Yusuf, MD
Side effects in a trial with statin, placebo and tablet-free periods
3' education - Nov. 16, 2020 - Prof. Darrel Francis, MD
Introduction: The evolving role of triglycerides
10' education - Nov. 15, 2020 - Prof. Peter LIbby, MD
No effect of omega-3 fatty acids and vitamine D supplements on incident AF
3' education - Nov. 15, 2020 - Christine Albert, MD
The six pillars of therapy in HFrEF
3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD
Benefit with cardiac myosin activator in HFrEF
3' education - Nov. 14, 2020 - Prof. John Teerlink, MD
Detection of widespread atherosclerosis in Swedish population
3' education - Nov. 14, 2020 - Prof. Göran Bergström, MD, PhD
Lessons from REDUCE-IT
10' education - Nov. 12, 2020 - Prof. Deepak Bhatt, MD - Online CME
Introduction: PCSK9i & LDL-c - Guidelines, Practice & Innovation
10' education - Nov. 9, 2020 - Prof. John Kastelein, MD
The role of GLP-1 receptor agonists in CVD prevention
10' education - Nov. 6, 2020 - Prof. Kamlesh Khunti, MD - Online CME
Time to reduce implementation gaps of lipid-lowering therapy
10' education - Nov. 6, 2020 - Prof. Kausik Ray, MD - Online CME
Introduction: Lp(a), a new lipid frontier in CV risk management & target for therapy
10' education - Nov. 3, 2020 - Prof. Erik Stroes, MD
Is there a role for PCSK9 inhibition in patients with high Lp(a)?
10' education - Nov. 2, 2020 - Prof. Vera Bittner, MD - Online CME
Combination therapy to achieve lower LDL-c goals is the way forward
3' education - Oct. 27, 2020 - Prof. Kausik Ray, MD
Novel strategies to lower Lp(a)
10' education - Oct. 27, 2020 - Prof. Sam Tsimikas, MD - Online CME
Latest results with non-LDL lowering agents in reducing CV risk
10' education - Oct. 26, 2020 - Prof. Ulrich Laufs, MD
Introduction: Optimizing RAASi treatment through long-term potassium control
10' education - Oct. 22, 2020 - Prof. Peter van der Meer, MD
Novel potassium binders to improve management of chronic HF
10' education - Oct. 21, 2020 - Prof. Javed Butler, MD - Online CME
The role for primary care in reducing CV risk in diabetes
10' education - Oct. 20, 2020 - Prof. Richard Hobbs, MD - Online CME
Non-LDL-c parameters in CV risk management and guidelines
10' education - Oct. 13, 2020 - Prof. Kausik Ray, MD - Online CME
Understanding risk of hyperkalemia in heart failure
10' education - Oct. 8, 2020 - Prof. Piotr Ponikowski, MD, PhD - Online CME
Why worry about high Lp(a) and how to assess Lp(a) levels?
10' education - Oct. 7, 2020 - Pia Kamstrup, MD, PhD - Online CME
Strong evidence for colchicine in patients with chronic coronary disease
5' education - Oct. 7, 2020 - Aernoud Fiolet, MD and prof. Jan Hein Cornel, MD, PhD
Huge advantage with ANGPTL3 inhibitor for HoFH patients with minimal to zero LDLR activity
3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD
A novel small binding protein that targets PCSK9
3' education - Oct. 6, 2020 - Prof. Evan Stein, MD, PhD
Small interfering RNA against PCSK9 reduces LDL-c in HeFH independent of genotype
3' education - Oct. 6, 2020 - Prof. Frederick Raal, MD
Introduction: Expanding focus for cardiologists - The patient with diabetes and cardiovascular outcomes
10' education - Oct. 3, 2020 - Prof. Ulf Landmesser, MD
Five years of PCSK9i - Lessons from practice: Which patients benefit most?
10' education - Sep. 30, 2020 - Prof. Erik Stroes, MD - Online CME
Updates in the 2019 ESC/EAS guidelines for the management of dyslipidemia
10' education - Sep. 29, 2020 - Prof. François Mach, MD
Changing paradigm in prediabetes and CVD: Potential for new concepts and new tools
10' education - Sep. 28, 2020 - Prof. John E Deanfield, MD - Online CME
The residual risk challenge in CVD: How important are triglycerides?
10' education - Sep. 25, 2020 - Prof. Ulf Landmesser, MD
Cardiovascular outcomes & atherosclerosis: How do GLP-1RA provide benefit?
10' education - Sep. 24, 2020 - Jorge Plutzky, MD - Online CME
Discussion: Novel opportunities tackling residual cardiovascular risk: The evolving role of triglycerides
10' education - Sep. 23, 2020
A marriage of clinical trial results and imaging findings with icosapent ethyl
10' education - Sep. 21, 2020 - Fabrice Martens, MD, PhD, prof. Matthew Budoff, MD and prof. Gabriel Steg MD
Heart failure, a multimorbid syndrome: An increasing challenge to manage
10' education - Sep. 21, 2020 - Prof. Carolyn Lam, MD, PhD - Online CME
One year after the new ESC/EAS dyslipidemia guidelines
10' education - Sep. 17, 2020 - Prof. François Mach - Online CME
New potassium binders for management of hyperkalemia in HF
10' education - Sep. 16, 2020 - Prof. Faiez Zannad, MD
No difference in outcomes after 5 years with anti-ischemic metabolic agent in patients after PCI
3' education - Sep. 15, 2020 - Prof. Freek Verheugt
Setting a patient on the right track following hospitalization for ADHF
15' education - Sep. 14, 2020 - Alexander Cadenbach, MD and prof. Mark Petrie, MD - Online CME
Panel discussion: Expanding focus for cardiologists - The diabetic patient and cardiovascular outcomes
10' education - Sep. 9, 2020 - Prof. Ulf Landmesser - Online CME
The cardiology challenge to manage CV risk in diabetes
10' education - Sep. 9, 2020 - Prof. Nikolaus Marx, MD - Online CME
Iron deficiency in patients with heart failure
10' education - Sep. 8, 2020 - Niels Grote Beverborg, MD, PhD
Incredible consistency between two SGLT2i trials in HFrEF
3' education - Sep. 7, 2020 - Milton Packer, MD
No clinical benefit from suspending ACEi/ARBs in hospitalized patients with COVID-19
3' education - Sep. 7, 2020 - Prof. Renato D. Lopes, MD, PhD
Updates in the 2020 AF guidelines
3' education - Sep. 2, 2020 - Prof. Isabelle van Gelder, MD
How to diagnose and treat amyloidosis?
10' education - Sep. 1, 2020 - Prof. Peter van der Meer, MD, PhD
SGLT2 inhibitors: a new foundation in heart failure or another diuretic?
10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD
BP lowering should be considered irrespective of prior CVD or baseline SBP
3' education - Sep. 1, 2020 - Kazem Rahimi, MD
Advantages of the digital 2020 ESC Congress
3' education - Sep. 1, 2020 - Prof. Barbara Casadei, MD
Colchicine reduces primary outcome in chronic coronary disease
3' education - Aug. 31, 2020 - Mark Nidorf, MD
Triage strategy for outpatient management of PE patients based on HESTIA non-inferior to sPESI
5' education - Aug. 31, 2020 - Prof. Menno Huisman, MD
A step ahead in the management of HFmrEF and HFpEF
3' education - Aug. 31, 2020 - Prof. Burkert Pieske, MD
Nephroprotective effects with SGLT2i in CKD patients
3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD
Huge impact of COVID-19 outbreak on patients with diseases that can normally be treated
3' education - Aug. 30, 2020 - Prof. Barbara Casadei, MD
Aspirin superior to DAPT for bleeding in patients treated with TAVI
3' education - Aug. 30, 2020 - Jorn Brouwer, MD
Succes with SGLT2 inhibitor in HFrEF for all three end points
3' education - Aug. 29, 2020 - Milton Packer, MD
Early rhythm control in AF patients improves outcomes
3' education - Aug. 29, 2020 - Prof. Paulus Kirchhof, MD
Remarkably similar findings with another SGLT2i in HFrEF
3' education - Aug. 29, 2020 - Prof. John McMurray
How will outcomes of ARNI trials impact diagnosis and management of HF?
10' education - Aug. 26, 2020 - Prof. Mark Petrie, MD
3rd Groningen Heart failure symposium: How to implement the newest HF therapies?
10' education - Aug. 25, 2020 - Prof. Dirk Jan van Veldhuisen, MD and prof. Adriaan Voors, MD
Burden of residual risk: Are triglycerides a risk marker?
10' education - Aug. 18, 2020 - Prof. Klaus Parhofer, MD
Cardiac abnormalities in recovered COVID-19 patients
3' education - July 29, 2020 - Prof. Rudolf de Boer, MD, PhD
MI more often missed in women
5' education - July 28, 2020 - Yldau van der Ende, MD, PhD
Getting better at diagnosing HFpEF - sharing clinical practice experience
15' education - July 28, 2020 - Prof. Mark Petrie, MD and Pardeep Jhund, MD, PhD - Online CME
Targeting kidney outcomes in DKD: Can GLP-1RA provide kidney protection?
10' education - July 21, 2020 - Prof. Johannes Mann, MD
Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?
10' education - July 14, 2020 - Prof. Christoph Wanner, MD
Familial Hypercholesterolemia and Lp(a)
10' education - July 14, 2020 - Nick Nurmohamed, MD
Improving outcomes for patients following an admission with ADHF
15' education - July 7, 2020 - Prof. Mark Petrie, MD and Klaus Witte, MD - Online CME
Diabetes and CKD: is it all about managing glucose?
10' education - July 1, 2020 - Prof. Melanie Davies, MD
Familial Hypercholesterolemia: Why and how to screen?
10' education - June 30, 2020 - Prof. Kees Hovingh, MD, PhD
The cardiorenal connection and diabetes: Exploring intervention by SGLT2i
10' education - June 23, 2020 - Maria Rosa Costanzo, MD
Tools to detect FH
10' education - June 23, 2020 - Rens Reeskamp, MD
DKD and CV risk: What is the potential of targeting GLP-1?
10' education - June 16, 2020 - Prof. Erik Stroes, MD
No major effect of eGFR dip on reduction of incident or worsening nephropathy by SGLT2i
5' education - June 11, 2020 - Bettina Kraus, MD
Kidney protection and SGLT2i: What do we know?
10' education - June 9, 2020 - Prof. Mark Cooper, MD
Familial hypercholesterolemia in children and adolescents
10' education - June 2, 2020 - Bert Wiegman, MD, PhD
Treatment goals for LDL-c-lowering and emerging evidence for the importance of Lp(a)
10' education - May 26, 2020 - Prof. J. Wouter Jukema, MD - Leiden, The Netherlands
Reduction of revascularization with icosapent ethyl in patients with hypertriglyceridemia
3' education - May 25, 2020 - Benjamin Peterson, MD
Increase in out-of-hospital cardiac arrest during the COVID-19 outbreak in Lombardy, Italy
3' education - May 8, 2020 - Enrico Baldi, MD
Venous thromboembolism in COVID-19 patients
5' education - May 6, 2020 - Prof. Saskia Middeldorp
Obesity as a risk factor for severity of COVID-19: multiple potential mechanisms
5' education - May 1, 2020 - Prof. Naveed Sattar, MD
COVID-19, ACE2 and RAAS inhibition
Lecture - Apr. 29, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
COVID-19 associated thrombotic complications
5' education - Apr. 22, 2020 - Erik Klok, MD, PhD
COVID-19, ACE2 and RAASi - a scientific perspective
10' education - Apr. 19, 2020 - Prof. Jan Danser, PhD
A clinical perspective on COVID-19, ACE2 and RAAS inhibition
10' education - Apr. 18, 2020 - Prof. Murray Epstein, MD
COVID-19, ACE2 and RAAS inhibition: What are the implications for practice?
10' education - Apr. 17, 2020 - Profs. John Deanfield, Jan Danser and Murray Epstein
One step closer to controlling LDL-c levels in HoFH with PCSK9i
3' education - Apr. 9, 2020 - Dirk Blom, PhD
Use of ARNI in HFpEF patients reduces NT-proBNP levels
3' education - Apr. 8, 2020 - Jonathan Cunningham, MD
Reduced bleeding with P2Y12i monotherapy after 3 months DAPT after complex PCI
3' education - Apr. 7, 2020 - Prof. George Dangas, MD, PhD - ACC 2020
Stopping with aspirin after 3 months DAPT is safe in a wide range of patients
3' education - Apr. 2, 2020 - Prof. Freek Verheugt, MD
Mechanistic underpinning of CV benefit observed with icosapent ethyl
3' education - Apr. 2, 2020 - Prof. Deepak Bhatt, MD - ACC 2020
Remarkable reduction of LDL-c with antibody against angiopoietin-like protein 3 in HoFH
3' education - Apr. 1, 2020 - Prof. Frederick Raal, PhD - ACC 2020
Higher rate of smoking cessation with e-cigarettes compared to counseling
3' education - Apr. 1, 2020 - Prof. Mark Eisenberg, MD - ACC 2020
Added value of sGC stimulator in worsening HFrEF patients
3' education - Mar. 31, 2020 - Prof. Paul Armstrong, MD - ACC 2020
CAPACITY COVID: a registry of CV variables in patients with COVID-19
3' education - Mar. 31, 2020 - Prof. Folkert Asselbergs, MD, PhD
Oral anticoagulant monotherapy reduces bleeding in AF patients after TAVI
3' education - Mar. 30, 2020 - Dr. Jur ten Berg, MD, PhD - ACC 2020
NOAC plus aspirin superior to aspirin alone for preventing major adverse limb and CV events
3' education - Mar. 29, 2020 - Dr. Marc P. Bonaca, MD - ACC 2020
Consistent findings with NOAC plus aspirin in CAD and PAD with and without diabetes
3' education - Mar. 29, 2020 - Prof. Deepak Bhatt, MD - ACC 2020
NOAC non-inferior to heparin in reducing cancer-associated VTE recurrence
10' education - Mar. 29, 2020 - Prof. Menno Huisman - ACC 2020
Lp(a) and immune metabolism
5' education - Mar. 12, 2020 - EAS-endorsed Lp(a) satellite meeting - Jeffrey Kroon, PhD
Challenges in prescribing DOACs for stroke prevention in AF
5' education - Mar. 2, 2020 - Prof. Freek Verheugt and John Eikelboom
Addressing lipid risk: a system-wide approach to implementation
5' education - Feb. 27, 2020 - Jorge Plutzky, MD
Lipids beyond LDL-c: HDL-c and triglycerides
5' education - Feb. 25, 2020 - Prof. Peter Libby, MD
Patient-reported cognition at the end of a PCSK9 antibody trial
5' education - Nov. 17, 2019 - Baris Gencer, MD
Translating ESC/EAS Dyslipidemia Guidelines to clinical practice
10' education - Feb. 18, 2020 - Prof. Kausik Ray, MD
Assessing residual lipid risk with advanced testing
5' education - Feb. 17, 2020 - Samia Mora, MD
Reducing triglycerides in REDUCE-IT
10' education - Feb. 11, 2020 - Prof. Deepak Bhatt, MD - Online CME
Addressing CV risk: the role of statins and ezetimibe
5' education - Feb. 9, 2020 - Prof. Christopher Cannon, MD
The spectrum of triglyceride-containing lipoproteins
10' education - Feb. 4, 2020 - Jorge Plutzky, MD - Online CME
The mechanism of action of bempedoic acid
Feb. 2, 2020
Treatment benefit with PCSK9 antibody in patients with recent vs. remote MI
5' education - Feb. 2, 2020 - Baris Gencer, MD
GLP-1RA treatment effect in patients with T2DM and PAD
5' education - Jan. 8, 2020 - Prof. Subodh Verma, MD, PhD
Translating pathophysiological, genetic and trial data to practical LDL-c treatment recommendations
10' education - Dec. 19, 2019 - Professor Ulrich Laufs, MD, PhD
HFpEF: A misunderstood disease in search of a therapy
10' education - Jan. 23, 2020 - Prof. Scott Solomon
The safety of PCSK9 inhibitors - how low can we go?
5' education - Jan. 22, 2020 - Robert Giugliano, MD
Rationale of new recommendations in ESC/EAS Guidelines for Dyslipidemia
10' education - Dec. 19, 2019 - Prof. Ulf Landmesser, MD
More insight into daily clinical practice and more collaboration needed to improve diabetes care
3' education - Oct. 8, 2019 - Prof. Chantal Mathieu, MD, PhD
Novel recommendations in the 2019 ESC/EASD diabetes guidelines and why we need them
5' education - Oct. 8, 2019 - Prof. Francesco Cosentino - European Diabetes Policy Summit
How can triglycerides increase CV risk?
10' education - Jan. 16, 2020 - Prof. Børge Nordestgaard, MD
The growing global challenge of CV risk
5' education - Jan. 15, 2020 - Thomas Gaziano, MD
Effects of ARNI treatment on arterial hemodynamics, cardiac remodelling and pulmonary artery pressure in HFrEF
5' education - Jan. 14, 2020 - Akshay S. Desai, MD
LDL-c, atherosclerotic plaques and CV risk - what to do about it
10' education - Jan. 14, 2020 - Prof. Thomas Lüscher, MD
Barriers to implementation of diabetes guidelines
5' education - Oct. 8, 2019 - Prof. Roger Lehmann - European Diabetes Policy Summit
Heart failure with mid-range ejection fraction
10' education - Jan. 6, 2020 - Prof. Burkert Pieske, MD
The burden of residual CV risk in the statin era
5' education - Jan. 6, 2020 - Erin Bohula, MD
Efficacy and safety of ARNI in high-risk patients in the PIONEER-HF trial
5' education - Dec. 19, 2019 - Prof. David Morrow, MD
Three lines of evidence for triglycerides as a CV risk factor
10' education - Dec. 17, 2019 - Prof. Ph. Gabriel Steg
PARADIGM-HF and PARAGON-HF: Redefining HFrEF and HFpEF
10' education - Dec. 10, 2019 - Milton Packer, MD
Effect of BET inhibition on CV outcomes in ACS and diabetes patients
10' education - Dec. 9, 2019 - Prof. Kausik Ray, MD
New tool can help identify FH patients
3' education - Nov. 17, 2019 - Willem Bax, Alkmaar - AHA 2019, Philadelphia
Improved health status with SGLT2-inhibitor in HFrEF
3' education - Nov. 25, 2019 - Prof. Mikhail Kosiborod - AHA 2019, Philadelphia
A rise in adverse clinical events with NOAC-regime after TAVR resulted in termination of trial
3' education - Nov. 25, 2019 - Prof. Freek Verheugt - AHA 2019, Philadelphia
Possible favorable effects of icosapent ethyl on plaque-parameters
3' education - Nov. 25, 2019 - Prof. Stephen Nicholls - AHA 2019, Philadelphia
Single dose colchicine prior to PCI reduces rise in inflammation, but does not give reduction in MI and MACE
3' education - Nov. 25, 2019 - Binita Shah - AHA 2019, Philadelphia
More evidence that aspirin may not be necessary in long-term antiplatelet therapy after ACS
3' education - Nov. 18, 2019 - Usman Baber - AHA 2019, Philadelphia
Is HF the same disease across the EF spectrum, or does HF have two physiologies that respond differently to treatment?
3' education - Nov. 18, 2019 - Prof. Lynne Stevenson - AHA 2019, Philadelphia
ARNI seems to give CV benefit not only in HFrEF, but up to EF of about 60%
3' education - Nov. 18, 2019 - Prof. Scott Solomon - AHA 2019, Philadelphia
Fish oil treatment reduces several plaque parameters after 9 months
3' education - Nov. 18, 2019 - Prof. Matthew Budoff - AHA 2019, Philadelphia
Benefit on QoL with revascularization proportional to severity of angina symptoms
3' education - Nov. 18, 2019 - Prof. John Spertus - AHA 2019, Philadelphia
Patients with moderate ischemia on a stress test do not need to go straight to the cathlab
3' education - Nov. 18, 2019 - Prof. Donald Lloyd-Jones - AHA 2019, Philadelphia
Invasive vs. conservative strategy does not reduce CV events in patients with CKD and ischemia
3' education - Nov. 17, 2019 - Sripal Bangalore, MD, New york - AHA 2019, Philadelphia
Succesful repurposing of an old anti-inflammatory drug for a new application
3' education - Nov. 16, 2019 - Aruna Pradhan, MD - AHA 2019, Philadelphia
New generation of teenagers made addicted to nicotine: it is time to act
3' education - Nov. 16, 2019 - Mariell Jessup, MD - AHA 2019, Philadelphia
Treatment with anti-inflammatory agent reduces both first and recurrent events post-MI
3' education - Nov. 16, 2019 - Jean-Claude Tardif, MD, Canada - AHA 2019, Philadelphia
PCSK9 siRNA, on top of maximally tolerated statin therapy, potently lowers LDL-c
3' education - Nov. 16, 2019 - R. Scott Wright, MD, Rochester, MN, USA - AHA 2019, Philadelphia
Consistent CV benefit and tolerability of SGLT2i in HF patients irrespective of diabetes
3' education - Nov. 16, 2019 - John McMurray, MD, Glasgow - AHA 2019, Philadelphia
Smartphone-based AF screening in the general population
5' education - Oct. 28, 2019 - Paris, France - Tine Proesmans
Hs-troponin measured 30 min after admission to diagnose MI
5' education - Oct. 24, 2019 - Paris, France - Camilla Bang, MD
Biochemical urine test to measure medical adherence in hypertension
5' education - Oct. 24, 2019 - Paris, France - Dan Lane
What are the most important changes in the 2019 ESC/EAS Dyslipidemia Guidelines?
5' education - Oct. 23, 2019 - Paris, France - Prof. François Mach, MD
Betablocker use associated with reduced mortality in HFrEF patients >80 years
5' education - Oct. 22, 2019 - Paris, France - Gianluigi Savarese, MD
Lessons from ISAR-REACT 5 about which antiplatelet agent to choose in ACS patients
3' education - Oct. 21, 2019 - Prof. Freek Verheugt, Amsterdam - ESC 2019, Paris
Mechanisms of action of GLP-1RAs
10' education - Oct. 21, 2019 - Prof. Filip Knop, MD
GLP-1RA: where do they fit in CV risk management?
10' education - Oct. 21, 2019 - Prof. John Deanfield, MD
Sex-related differences in ACS patients
5' education - Oct. 15, 2019 - Paris, France - Sanne Peters, PhD
NP metabolism associated with clinical outcomes in HF
5' education - Oct. 15, 2019 - Frank Gommans, MD, PhD
Heterogeneity of treatment effects from intensive lifestyle intervention on CV events in T2DM
5' education - Oct. 15, 2019 - Paris, France - Jan Westerink, MD, PhD
Heart Failure: What are the practical consequences of current and ongoing SGLT2i outcome trials?
10' education - Oct. 15, 2019 - Prof. Faiez Zannad, MD
CRP levels associated with risk of cancer in stable CVD
5' education - Oct. 14, 2019 - Paris, France - Cilie van ’t Klooster, MD
Estimating individual lifetime benefit and bleeding risk with NOAC addition to asprin in stable CVD
5' education - Oct. 14, 2019 - Paris, France - Tamar de Vries, MD
A transatlantic discussion on the new LDL-c guidelines: What are the key differences?
10' education - Oct. 11, 2019 - Prof. Christie Ballantyne, MD
CVD in women
3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Cecilia Linde - ESC 2019, Paris
What is mendelian randomization?
5' education - Oct. 10, 2019 - Paris, France - Prof. Børge Nordestgaard
A life course perspective on benefits of lower cholesterol
5' education - Oct. 9, 2019 - ESC 2019, Paris, France - George Thanassoulis
A revolution in treatment of HFrEF with a SGLT2 inhibitor
5' education - Sep. 1, 2019 - Paris, France - Prof. Subodh Verma, MD, PhD
No improved clinical outcomes with remote ischemic conditioning in STEMI patients undergoing PCI
3' education - Oct. 7, 2019 - Prof. Hans Erik Botker - ESC 2019, Paris
The diabetes challenge for cardiologists: The key things to understand
10' education - Sep. 2, 2019 - Prof. Naveed Sattar, MD
LDL-c targets in the ESC/EAS dyslipidaemia guidelines in a nutshell
10' education - Oct. 4, 2019 - Prof. Brian Ference, MD
Heart & Kidney interactions: What are the challenges for prevention and protection?
10' education - Sep. 2, 2019 - Prof. Christoph Wanner
Clinical update on BET inhibition: The patient profile that may benefit from BET inhibition
10' education - Aug. 31, 2019 - Prof. Kausik Ray, MD
BET inhibition, an epigenetic pathway: How could BET inhibition modulate atherothrombotic risk?
10' education - Sep. 30, 2019 - Prof. Wouter Jukema
The 2019 ESC/EASD diabetes guidelines: a major paradigm shift in the management of T2DM
10' education - Sep. 30, 2019 - Paris, France - Prof. Francesco Cosentino, MD
Reduced long-term CV death and MI with complete multivessel revascularization in STEMI
3' education - Sep. 25, 2019 - Paris, France - Prof. Shamir Mehta
Insights and lessons from the ODYSSEY Outcomes trial: Which patients benefit most?
10' education - Sep. 28, 2019 - Paris, France - Prof. Ph. Gabriel Steg, MD - Online CME
Challenges in targeting residual risk in diabetic patients, post ACS
10' education - Sep. 25, 2019 - Prof. Peter Libby, MD
Extending the evidence: What did the FOURIER trial teach us on managing high-risk patients?
10' education - Sep. 24, 2019 - Prof. Marc S. Sabatine, MD
Targeting PCSK9: Expanding knowledge and targeting new frontiers
10' education - Sep. 24, 2019 - Paris, France - Prof. John Kastelein, MD
Cardioprotective mechanisms of SGLT2 inhibitors: What do cardiologists need to know?
10' education - Sep. 24, 2019 - Prof. Nikolaus Marx, MD
Substantial reduction in LDL-c with PCSK9i in the very high-risk acute setting of ACS
5' education - Sep. 24, 2019 - Paris, France - Konstantinos C. Koskinas, MD
Reduced LDL-c with PCSK9 inhibitor in acute setting of ACS
5' education - Aug. 31, 2019 - Paris, France - Prof. François Mach
No beneficial effects of oxygen use in subjects with a heart attack
3' education - Sep. 2, 2019 - ESC 2019, Paris - Prof. Ralph Stewart, New Zealand
Decreased CV risk with an intervention targeting identified barriers to care
3' education - Aug. 31, 2019 - ESC 2019, Paris - Prof. J-D Schwalm
Almost significant effects on CV outcomes with ARNI in HFpEF
3' education - Sep. 23, 2019 - Paris, France - Prof. Dirk Jan van Veldhuisen, MD
Reduced NT-proBNP associated with reverse cardiac remodeling after initiation of ARNI in HFrEF
5' education - Sep. 20, 2019 - Paris, France - James Januzzi, MD
Long-term exposure to modestly lower LDL-c and SBP substantially reduces lifetime CV risk
5' education - Sep. 19, 2019 - Brian Ference, MD - Cambridge, UK
LDL-c lowering with twice-a-year injection of siRNA against PCSK9: The ORION-11 trial
10' education - Sep. 16, 2019 - Prof. John Kastelein
The 2019 ESC/EAS Dyslipidemia Guidelines from the point of view of the European Atherosclerosis Society
5' education - Sep. 12, 2019 - Prof. Alberico Catapano
Long-term treatment with dual antiplatelet therapy in patients with diabetes and stable CAD
3' education - Sep. 9, 2019 - Prof. Ph. Gabriel Steg
Large community-based studies stress the impact of preventive measures
3' education - Sep. 9, 2019 - Paris, France - Prof. Salim Yusuf
Rationale for the lower LDL-c targets in the 2019 ESC/EAS Dyslipidemia Guidelines
5' education - Sep. 9, 2019 - Paris, France - Prof. François Mach
Importance of continuous use of secondary prevention therapy after CABG
3' education - Sep. 3, 2019 - Erik Björklund
A one-hour hs-troponin protocol in ACS suspected patients resulted in more rapid discharge
3' education - Sep. 3, 2019 - Prof. Derek Chew
Reduction in bleeding with genotype-guided strategy for choice of P2Y12i in STEMI patients
3' education - Sep. 3, 2019 - Danny Claassens
All-cause mortality benefit with ICD use in STEMI patients treated with primary PCI
3' education - Sep. 3, 2019 - Danielle Haanschoten
Primary PCI is the best strategy for STEMI patients compared to fibrinolysis
3' education - Sep. 2, 2019 - Michael Maeng, MD
Clear results with NOAC monotherapy in patients with CAD and AF
3' education - Sep. 2, 2019 - Prof. Freek Verheugt
10-year outcomes with CABG versus PCI in patients with three-vessel disease or left main CAD
3' education - Sep. 2, 2019 - Daniel Thuijs
Early and sustained vasodilation strategy fails to improve outcomes in acute HF
3' education - Sep. 2, 2019 - Prof. Christian Müller
Community-wide salt restriction reduces blood pressure and incidence of hypertension
3' education - Sep. 2, 2019 - Paris, France - Prof. Jaime Miranda
DAPT strategy results in favorable net clinical benefit in CAD patients with diabetes and prior PCI
3' education - Sep. 1, 2019 - Prof. Deepak Bhatt
Large risk reductions with SGLT2 inhibitor in HFrEF with or without diabetes
3' education - Sep. 1, 2019 - Paris, France - Prof. John McMurray
Head-to-head comparison of P2Y12-inhibitors in ACS yields surprising results
3' education - Sep. 1, 2019 - Paris, France - Prof. Stefanie Schüpke
Major benefits with implementation of rapid rule-out pathway for MI
3' education - Sep. 1, 2019 - Prof. Nicholas Mills
ARNI treatment in HFpEF shows benefit in secondary outcomes, but misses significance in primary endpoint
3' education - Sep. 1, 2019 - Prof. Scott Solomon
The role of ALP as predictor of CV events and vascular calcification in CKD
10' education - June 15, 2019 - Dr. Mathias Haarhaus, MD
Structural determinants of Lp(a) pathogenicity
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Marlys Koschinsky, PhD
Managing hyperkalemia in cardiorenal patients: novel therapeutic insights to optimize outcomes
10' education - Aug. 28, 2019 - Prof. Matthew Weir, MD - Online CME
Are we ready for prime-time Lp(a) assay standardization?
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Santica Marcovina
LDL vs Lp(a) cholesterol: confounding
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Calvin Yeang, MD, PhD
Incident hyperkalemia, RAASi use and outcomes in acute hospitalized HF patients
5' education - Aug. 26, 2019 - Joost Beusekamp
The science behind vascular and renal benefits of GLP-1 receptor agonists
10' education - June 12, 2019 - ERA-EDTA 2019 - Filip Krag Knop, MD - Online CME
Associations of Lp(a) with CV morbidity and mortality
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Pia Kamstrup, MD, PhD
Underlying mechanisms of nephroprotective effects with SGLT2i in CKD
10' education - June 14, 2019 - ERA-EDTA 2019 - Paola Fioretto, MD - Online CME
The clinical landscape of managing patients with CKD: Where are we now and what can we expect?
10' education - June 14, 2019 - ERA-EDTA 2019 - Will Herrington, MD - Online CME
Phase II data on Lp(a) lowering, followed by NHLBI recommendation
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Sam Tsimikas
Lp(a) contribution to PCSK9-antibody benefit in ODYSSEY-OUTCOMES and FOURIER
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Wouter Jukema, MD, PhD
A novel parameter for proximal tubular function in HF
5' education - Aug. 21, 2019 - Lisa Emmens
Addressing the risk of hyperkalemia in HF: is there a sweet spot for potassium binding?
10' education - Aug. 21, 2019 - Prof. van der Meer, MD, PhD - Online CME
Higher dose of loop diuretics limits uptitration RAASi in HFrEF
5' education - Aug. 20, 2019 - Jozine ter Maaten
Clinical outcomes of GLP-1RA in kidney disease: Current evidence and ongoing trials
10' education - July 12, 2019 - ERA-EDTA 2019 - Frederik Persson, MD - Online CME
Importance of protection and prevention in diabetic cardiorenal disease
10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. John Deanfield, MD - Online CME
Epigenetic mechanisms targeting ALP: A pathway for prevention of vascular calcification?
10' education - Aug. 7, 2019 - Marta Ruiz-Ortega, PhD
Understanding and managing obesity-related HFpEF
10' education - July 22, 2019 - Milton Packer, MD
Cardiac amyloidosis: an emerging target in HFpEF?
10' education - July 19, 2019 - Prof. van der Meer, MD, PhD
Heart failure and diabetes: What is the goal of treatment?
10' education - July 17, 2019 - Prof. John McMurray, MD
Entry of Lp(a) into the CV arena
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Florian Kronenberg, MD
RAAS inhibition in patients with kidney disease: Balancing the benefits and risks
10' education - July 12, 2019 - ERA-EDTA 2019 - Prof. Patrick Rossignol, MD - Online CME
Lp(a) apheresis and CVD risk modulation
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Elisa Waldmann, MD
Prevalence and relevance of elevated Lp(a) in familial hypercholesterolemia
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Prof. Børge Nordestgaard, MD
Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?
10' education - July 4, 2019 - ERA-EDTA 2019 - Rajiv Agarwal, MD - Online CME
Targeting residual cardiovascular risk & vascular calcification: The clinical perspective for BET inhibition
10' education - July 3, 2019 - ERA-EDTA 2019 - Vincent Brandenburg, MD
Assessing individual CV risk and treatment effect with U-Prevent
10' education - July 2, 2019 - Jannick Dorresteijn, MD, PhD
Lp(a) and calcification in aortic stenosis
5' education - May 24, 2019 - EAS-endorsed Lp(a) satellite meeting - Kang He Zheng, MD
Targeting CVD in diabetes: Novel strategies to tackle the risk
10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
The cardiovascular challenge for primary care in diabetes
10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
T2DM & CV outcomes: More than glucose management? - Lessons from GLP-1RA trials
10' education - Apr. 11, 2019 - EuroPrevent 2019 - Stephan Jacob, MD
The future of SGLT2i in HF: Managing patients without T2DM?
10' education - June 20, 2019 - ESC HF 2019 - Prof. Adriaan Voors, MD
Real world practices and outcomes in the management of HF in T2DM patients
10' education - June 20, 2019 - ESC HF 2019 - Prof. Carolyn Lam - Singapore
The known and unknown of SGLT2 inhibition in CKD
10' education - June 11, 2019 - ISN-WCN 2019 - Carol Pollock, MD
Efforts to move universal cholesterol screening before the age of 20 forward
3' education - May 29, 2019 - Maastricht, The Netherlands - Professor Kausik Ray, MD
Positive phase II trial data with novel anti-PCSK9 agent
3' education - May 29, 2019 - Maastricht, The Netherlands - Prof. Evan Stein, MD
More intelligent intervention through more strategic use of CV biomarkers
3' education - May 28, 2019 - Maastricht, The Netherlands
The essentials about diabetes and heart failure
10' education - June 19, 2019 - ESC HF 2019 - Prof. Martin Cowie - London, UK
Reduced Lp(a) with PCSK9 inhibitors in individuals with high Lp(a) at baseline contributes to CV risk reduction
3' education - May 29, 2019 - Maastricht. The Netherlands - Prof. Chapman, DSc
Why could patients with HF and T2DM benefit from SGLT2i?
10' education - June 12, 2019 - ESC HF 2019 - Prof. Subodh Verma - Toronto, ON, Canada
Growing importance of lowering remnants, also in light of the obesity epidemic
3' education - June 3, 2019 - Børge Nordestgaard
Moving from ignorance on the complexity of HDL to novel therapeutic opportunities
3' education - June 3, 2019 - John Chapman, DSc
ARNI as first-line therapy in de novo HFrEF patients after ADHF event
3' education - June 3, 2019
Potassium binder results in more persistent use of spironolactone in resistant hypertension and CKD, also in a group of HF
3' education - June 3, 2019
Effect of IL-1β inhibition on lung cancer sheds new light on the role of inflammation
3' education - May 28, 2019 - EAS 2019, Maastricht - Paul Ridker, MD
Genetic variants and elevated risk of CAD
3' education - May 28, 2019 - Heribert Schunkert, MD - Munich, Germany
Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes?
10' education - May 22, 2019 - ISN-WCN 2019 - Mark Cooper, MD
The clinical landscape of managing patients with CKD
10' education - May 21, 2019 - ISN-WCN 2019 - Prof. David Cherney - Toronto, ON, Canada
Positive results with SGLT2 inhibitor in patients with diabetic kidney disease across all levels of eGFR
3' education - Apr. 17, 2019
Reduction in renal outcomes with selective endothelin receptor antagonist in patients with diabetic kidney disease
3' education - Apr. 17, 2019 - Melbourne, Australia
Endothelin receptor antagonist gives renoprotection in selected patients with T2DM and CKD
3' education - Apr. 15, 2019 - Melbourne, Australia
Hopeful results with SGLT2 inhibitor in patients with T2DM and chronic kidney disease
3' education - Apr. 15, 2019 - Melbourne, Australia
Detection of AF with wearable technology to prevent stroke
3' education - Apr. 8, 2019
Improved QoL with transcatheter mitral valve repair in HF patients with secondary mitral regurgitation
3' education - Apr. 8, 2019
Centrifugal-flow pump superior to axial-flow pump for clinical outcomes in advanced HF
3' education - Apr. 8, 2019
No difference in survival with immediate vs. delayed coronary angiography after cardiac arrest in NSTEMI patients
3' education - Apr. 8, 2019 - Jorrit Lemkes
Clinical benefit with SGLT2 inhibitor in diabetes patients with HF independent of ejection fraction
3' education - Apr. 8, 2019 - Dr. Eri Kato, Kyoto, Japan
ACDF Brief comments: The evolving role of SGLT2 inhibitors
3' education - Apr. 3, 2019 - Hanoi, Vietnam - Prof Mark Cooper, Melbourne, Australia - Asian Cardio Diabetes Forum 2019
ACDF Brief comments: The evolving role of SGLT2 inhibitors in heart failure?
3' education - Apr. 3, 2019 - Hanoi, Vietnam - Asian Cardio Diabetes Forum 2019
ACDF Brief comments: Key challenges in reinforcing CV risk management among diabetic patients
3' education - Apr. 3, 2019 - Hanoi, Vietnam - Prof John E Deanfield - Asian Cardio Diabetes Forum 2019
ACDF Brief comments: What has changed significantly in evaluating and considering CV risk in managing patients with diabetes?1
3' education - Apr. 3, 2019 - Hanoi, Vietnam - Prof. John E Deanfield - Asian Cardio Diabetes Forum 2019
Challenges for screening and treatment of FH patients in clinical cardiology
5' education - Feb. 13, 2019 - Kausik Ray, Kees Hovingh - Online CME
Lecture: The Kidney: Opportunities for protection and prevention
Lecture - Mar. 31, 2019 - Hanoi, Vietnam
Lecture: Heart Failure: The next frontier for SGLT2 inhibitors?
Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. Nikolaus Marx, Aachen, Germany
Lecture: Targeting risk in patients with CVD, Diabetes or CKD: new guidelines and risk management approaches
Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. John E Deanfield, MD London, United Kingdom
Lecture: SGLT2 inhibition in CVD & Diabetes: How can we explain the benefits?
Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. Nikolaus Marx, Aachen, Germany
Lecture: Cardiovascular outcomes that will change diabetes practice: What are the key findings from recent trials
Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof Mark Cooper, MD Melbourne, Australia
Lecture: Targeting HbA1c in diabetes management: What are the key lessons from glucose lowering trials?
Lecture - Mar. 31, 2019 - Hanoi, Vietnam - Prof. Nikolaus Marx, Aachen, Germany
Device safely keeps HF patients out of the hospital
3' education - Mar. 17, 2019
Long-term data confirm safety and efficacy of oral antibiotics in left-sided endocarditis
3' education - Mar. 27, 2019
TAVR vs surgery in aortic stenosis: reason for a paradigm flip?
3' education - Mar. 19, 2019 - New Orleans, LA, USA - Janet Wyman
Highly purified omega-3 fatty acid not only lowers first ischemic events, but also recurrent events
3' education - Mar. 19, 2019 - Deepak L. Bhatt, MD
Benefits of early initiation of ARNI in acute HF confirmed in open-label extension study
3' education - Mar. 19, 2019 - Adam DeVore, MD
Cholesterol synthesis inhibitor has potential to be add-on therapy to statin in patients with high CV risk
3' education - Mar. 19, 2019 - Anne Carol Goldberg, MD
Substantial reduction in clinical outcomes with TAVR in aortic stenosis patients at low surgical risk
3' education - Mar. 19, 2019 - New Orleans, LA, USA - Martin B. Leon, MD
Better outcomes in patients with AF and ACS/PCI with NOAC vs. VKA and when dropping aspirin
3' education - Mar. 17, 2019 - New Orleans, LA, USA - John Alexander, MD
Proof-of-concept study shows 84% true AF in those with irregular pulse detected with smartwatch
3' education - Mar. 16, 2019 - New Orleans, LA, USA - Michael Valentine, MD
Lifestyle improvement forms foundation of comprehensive guideline for primary prevention
3' education - Mar. 16, 2019 - New Orleans, LA, USA - Dr. Amit Khera
New overarching recommendations in primary prevention guideline should help implementation of advise
3' education - Mar. 16, 2019 - New Orleans, LA, USA - Donna Arnett, MD
How are the guidelines for progressive CAD guiding us in clinical practice?
5' education - Dec. 13, 2018 - John Kastelein, Ulf Landmesser - Online CME
Lecture: Understanding the mechanism of CV benefit: How can we explain the results of GLP-1 outcome trials
Lecture - Mar. 1, 2019 - Abu Dhabi, UAE - Stephan Jacob, MD - Tubingen, Germany
Lecture: Screening for dysglycaema - when is it meaningful and how should it be performed?
Lecture - Mar. 1, 2019 - Abu Dhabi, AE - Lars Ryden, MD -Stockholm, Sweden
Lecture: Managing glucose in patients with diabetes and CVD: What did the clinical trials tell us so far?
Lecture - Mar. 1, 2019 - Abu Dhabi, UAE - Stephan Jacob, MD - Tubingen, Germany
Progressive CAD despite low LDL-C, an elusive disease?
5' education - Feb. 13, 2019 - Kausik Ray, Wouter Jukema - Online CME
New recommendations of the ESC/ESH Guidelines on the management of hypertension
3' education - Feb. 11, 2019 - Prof. Bryan Williams - London, UK
Lecture: Clinical trials in T2DM & CVD: Review of key outcomes with GLP-1 RA and SGLT2i
Lecture - Nov. 16, 2018 - Dubai, UAE - Prof. Eduard Montanya Barcelona, Spain
Lecture: Shifting gears in CVD & T2DM: What is the rationale for new diabetes interventions in the course of CVD?
Lecture - Nov. 16, 2018 - Dubai, UAE - Prof John E Deanfield, London, United Kingdom
Lecture: Translating mechanisms to benefits: How can we explain the cardiovascular benefits of new diabetes drugs?
Lecture - Nov. 16, 2018 - Dubai, UAE - Dr Adie Viljoen Stevenage, United Kingdom
Lecture: Targeting CV risk: Implications for clinical management of patients with T2DM & CVD
Lecture - Nov. 16, 2018 - Dubai, UAE - Prof Richard Hobbs, Oxford, United Kingdom
Lecture: The GLP1 landscape - refining our understanding
Lecture - Nov. 17, 2018 - Dubai, UAE - Dr Adie Viljoen, Stevenage, United Kingdom
Lecture: Screening for Diabetes: When is it meaningful and how should it be performed
Lecture - Nov. 17, 2018 - Dubai, UAE - Prof. Lars Ryden, Stockholm, Sweden
Lecture: Managing diabetes in daily cardiovascular practice: Potential barriers and solutions
Lecture - Nov. 17, 2018 - Dubai, UAE - Prof. Richard Hobbs, Oxford
Lecture: Diabetes: The new challenge in cardiovascular risk management
Lecture - Nov. 16, 2018 - Dubai, UAE - Prof Lars Ryden, Stockholm, Sweden
Lecture: The clinical landscape for T2DM and CVD: impact on guidelines and practice
Lecture - Nov. 16, 2018 - Dubai UAE - Prof John E Deanfield
Two choices of drugs that reduce CV risk in T2DM
3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Get involved in May Measurement Month to increase awareness of elevated blood pressure
3' education - Feb. 6, 2019 - Prof. Neil Poulter - London, UK
What are the key issues and challenges impacting clinical management with novel therapeutics lowering cholesterol?
5' education - Feb. 6, 2019 - Kausik Ray, Gilles Montalescot - Online CME
Diabetes & CVD: Time for a multifactorial approach
10' education - Dec. 6, 2018 - WCC Dubai, UAE - John E Deanfield, MD London, United Kingdom - Online CME
Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?
10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK - Online CME
Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control
10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain - Online CME
Aspirin for primary prevention of CV events: yes or no?
3' education - Jan. 30, 2019 - Prof. dr. Freek Verheugt - Amsterdam, The Netherlands
Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits
3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD
Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM
3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD
Cholesterol guidelines in need of major changes?
5' education - Jan. 25, 2019 - Kausik Ray, François Mach - Online CME
Are very low LDL-c levels safe?
5' education - Jan. 23, 2019 - John Kastelein, Lluis Masana - Online CME
LDL-c as target in cardiology: The road towards lower targets
5' education - Jan. 22, 2019 - John Kastelein, Chris Packard - Online CME
Identifying patients for PCSK9 therapy
10' education - Jan. 16, 2019 - Kees Hovingh, MD - Amsterdam, The Netherlands - Online CME
Guidelines and the role of non-statin therapies for high risk ASCVD patients
10' education - Jan. 7, 2019 - Wouter Jukema, MD - Leiden, The Netherlands - Online CME
A clinical view on BET inhibition in targeting residual risk in CVD and diabetes
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Kausik Ray, MD - London, UK
Targeting PCSK9 in clinical practice: Guidance & future
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands - Online CME
Landmark trials with PCSK9 inhibitors
10' education - Dec. 11, 2018 - Ph. Gabriel Steg, MD - Paris, France - Online CME
Moving to benefit-based medicine with a lifetime risk model
10' education - Dec. 10, 2018 - ESC 2018 - Munich, Germany - Prof. Frank Visseren - Utrecht, The Netherlands
Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?
10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden - Online CME
PCSK9 inhibitors: How do they work?
10' education - Dec. 4, 2018 - John Chapman - Paris, France - Online CME
Long term benefits of antihypertensive and cholesterol-lowering treatment in hypertension
10' education - Nov. 20, 2018 - Dr. Ajay Gupta - London, UK
Lp(a) lowering with PCSK9 inhibitor not enough to tackle artery wall inflammation
3' education - Dec. 3, 2018 - Prof. Erik Stroes, MD
Screening for high blood pressure globally
10' education - Nov. 20, 2018 - Dr. Thomas Beaney - London, Uk
HFpEF: Current and future clinical approaches to manage HFpEF
10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany - Online CME
GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control
10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark - Online CME
Unexpectedly large CV benefit with icosapent ethyl in statin-treated patients at high CV risk
3' education - Nov. 20, 2018 - Prof. Erik Stroes, MD
Lowering Lp(a) potently and safely with antisense technology
3' education - Nov. 20, 2018 - Sotirios Tsimikas, MD
Physical activity: every step counts, for everybody
3' education - Nov. 20, 2018 - Admiral Brett Giroir, MD - Washington, DC, USA
Vitamin D and omega-3 supplements did not meet primary cancer and CV endpoints in primary prevention cohort
3' education - Nov. 15, 2018 - JoAnn Manson, MD
Practice-changing results on in-hospital treatment of acute decompensated HF
3' education - Nov. 15, 2018 - Larry Allen, MD
Yoga-based cardiac rehabilitation program improves quality of life in post-MI patients
3' education - Nov. 15, 2018 - Dorairaj Prabhakaran, MD
Not all fish oils are created equal: different compounds have different effects
3' education - Nov. 13, 2018 - Deepak Bhatt, MD - Boston, MA, VS.
Initiation of ARNI in patients with acute decompensated heart failure
3' education - Nov. 13, 2018 - Eric Velazquez, MD
Comprehensive US approach to stimulate physical activity should tackle obesity and improve health
3' education - Nov. 13, 2018 - Dr. Ivor Benjamin - Milwaukee, WS, USA
It's too early for treatment withdrawal after recovery from dilated cardiomyopathy
3' education - Nov. 12, 2018 - Jane Wilcox, MD
New cholesterol guidelines help identify patients at highest risk who will benefit most from treatment
3' education - Nov. 11, 2018 - Neil Stone, MD - Evanston and Chicago, IL, USA
Highly purified EPA reduces important ischemic events in hypertriglyceridemia
3' education - Nov. 11, 2018 - Deepak Bhatt, MD - Boston, MA, USA.
SGLT2 inhibitor treatment may now be considered in broader T2DM population
3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.
Neutral study with methotrexate offers interesting insights on CV-relevant inflammatory pathway
3' education - Nov. 11, 2018
HFpEF: How to diagnose
10' education - Aug. 27, 2018 - Barry Borlaug - Rochester, MN, USA - Online CME
Shared decision-making with lifetime risk model
10' education - Nov. 5, 2018 - Dr. Jannick Dorresteijn - Utrecht, The Netherlands
How early do we see the CVD benefits of LDL-C lowering?
5' education - Oct. 31, 2018 - Philip Barter, MD - Sydney, Australia
HFpEF: What are the most likely pathophysiological mechanisms involved in the disease
10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore - Online CME
HFpEF: What is it & size of the problem
10' education - Aug. 27, 2018 - Prof. Adriaan Voors - Groningen, The Netherlands - Online CME
Diabetes & CVD: Time for a multifactorial approach
10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom - Online CME
The predictive role of biomarkers in CV risk assessment
10' education - Oct. 23, 2018 - Nina Paynter, PhD - Boston, MA, USA
Women are not a subgroup: the importance of sex-specific analyses
10' education - Oct. 23, 2018 - Dr. Jeanine Roeters van Lennep, Rotterdam, the Netherlands
U-prevent predicts lifetime risk of CV events in healthy individuals
10' education - Aug. 26, 2018 - Munich, Germany - Nicole Jaspers, MD – Utrecht, The Netherlands
Understanding epigenetics: The potential rationale for BET inhibition in management of CVD
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Jorge Plutzky, MD – Boston, MA, USA
LDL lowering versus LDL eradication; what makes clinical sense ?
10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John Kastelein, MD – Amsterdam, The Netherlands
SGLT2 inhibition in cardiology: What is the profile of benefit?
10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany
Population screening for atrial fibrillation with a smartphone
10' education - Aug. 26, 2018 - Munich, Germany - Prof. dr. Pieter Vandervoort - Genk, Belgium
Challenges and models in CV risk management: Start early, Invest in your arteries
10' education - Aug. 28, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom
Changing focus in diabetes: From glucose to CV risk management
10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany
What is the situation one year after the presentation about the CANTOS trial?
10' education - Aug. 26, 2018 - Munich, Germany - Prof. Paul Ridker, MD - Boston, MA, USA
The real residual risk in patients with CVD & diabetes: The promise of epigenetics
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands
Novel PCSK9 outcomes in perspective: Lessons from FOURIER & ODYSSEY
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Jennifer Robinson, MD - Iowa city, Iowa, USA - Online CME
PCSK9 as target for treatment: The genetic validation
10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Brian Ference, MD - Cambridge, UK - Online CME
Direct effects of iron on human cardiomyocytes
10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands
Managing potassium to optimize therapy in heart failure
10' education - Aug. 28, 2018 - Prof. Peter van der Meer, MD - Groningen, The Netherlands
Impressive results with transthyretin-stabilizer that reduces mortality and hospitalization in patients with transthyretin-related cardiomyopathy
3' education - Aug. 27, 2018 - Prof. Claudio Rapezzi, Bologna, Italy
Surprising result: Association very high levels of HDL-c and increased risk of CV events
3' education - Aug. 30, 2018 - Dr. Marc P Allard-Ratick, Atlanta, GA, VS
PCSK9 inhibitors may represent the first therapeutic means to lower Lp(a)
3' education - June 29, 2018 - John Chapman - Paris, France
Harmful effects of alcohol and smoking on arterial system in adolescents
3' education - Sep. 4, 2018 - Marietta Charakida, MD - London, UK
Learn more about the mission of PACE-CME
3' education - Aug. 31, 2018
Neutral outcomes for early intervention strategy compared to standard strategy in NSTEMI patients
3' education - Aug. 28, 2018 - Prof. Thomas Engstrom, Copenhagen, Denmark
Can sex-specific thresholds for hs-troponin improve diagnosis of myocardial infarction?
3' education - Aug. 28, 2018 - Prof. Nicholas Mills, Edinburgh, UK
Higher healthy diet score is associated with a lower risk of mortality and CV events across the globe
3' education - Aug. 28, 2018 - Dr. Andrew Mente, Hamilton, ONT, Canada
Direct Factor Xa inhibitor does not mitigate worsening of heart failure in HFrEF patients
3' education - Aug. 27, 2018 - Prof. Faiez Zannad, Vandoeuvre Les Nancy, France
In a primary prevention setting of diabetes patients, aspirin did not give overall benefit
3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK
P2Y12 inhibitor monotherapy for 23 months after 1 month of DAPT, compared to traditional 12-month DAPT
3' education - Aug. 27, 2018 - Prof. Patrick Serruys, Rotterdam, The Netherlands
Weight loss agent showed CV safety in high-risk patients with overweight or obesity
3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US
No CV benefit with omega-3 fatty acid supplements
3' education - Aug. 26, 2018
HFpEF: from understanding the physiology to development of new treatments
10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME
Laboratory investigation of lipids and lipoproteins
10' education - Aug. 21, 2018 - Prof. David Marais - Cape Town, South Africa
A clinical view on BET inhibition in CKD & CVD: Understanding recent data and future perspectives
10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Kamyar Kalantar-Zadeh, MD - Irvine, CA, USA
Cardiovascular disease in diabetes and CKD & residual risk: The promise of epigenetics
10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Erik Stroes - Amsterdam, The Netherlands
Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks
10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK
How much should Lp(a) be lowered to translate into meaningful CV benefit?
3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK
Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes
10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK - Online CME
Current management of heart failure and T2DM
10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK - Online CME
Advancing insights into Lp(a) as a causal factor in CVD
3' education - June 29, 2018 - John Chapman - Paris, France
Guidance from outcome trials: What are the clinical implications?
10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France - Online CME
Diabetes & Obesity in HFpEF: New targets in heart failure management
10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Prof. Rudolf de Boer - Groningen, The Netherlands - Online CME
Understanding CKD and SGLT2-inhibition: What are the key mechanisms?
10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland - Online CME
Atrial fibrillation & HFpEF: Novel device and therapeutic approaches
10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Dipak Kotecha - Birmingham, UK - Online CME
Mendelian randomization studies can inform study design of RCTs, to set up naturally randomized trials
3' education - June 29, 2018 - Brian Ference, MD - Cambridge, UK
Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials
10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom - Online CME
SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME
10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME
Dietary lipids in perspective
10' education - July 10, 2018 - Prof. David Marais - Cape Town, South Africa
Greater absolute benefit with PCSK9 inhibition in diabetes patients
3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
Epigenetics in CKD: Rationale for BET inhibition, an emerging therapeutic mechanism in renal disease and CVD
10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Louise Nordfors - Stockholm, Sweden
Estimating CV risk and treatment benefit
10' education - June 12, 2018 - Prof. Frank Visseren - Utrecht, The Netherlands - Online CME
Practical management of cardiovascular risk: Lessons from latest diabetes trials
10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Diabetes: How to reduce risk from a cardiovascular perspective?
10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands - Online CME
Importance of hypertension in CVD prevention
10' education - June 12, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Translation of novel approaches in CVD & diabetes to clinical practice
10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop - Online CME
The cardiovascular challenge for primary care in diabetes
10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME
Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment
10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands
The role of lipids in CVD prevention: Lessons learned about statins
10' education - June 6, 2018 - Prof. Kees Hovingh - Amsterdam, The Netherlands - Online CME
Familial hypercholesterolemia: Diagnosis and management
10' education - Apr. 10, 2018 - Prof. Frederick Raal - Johannesburg, South Africa
Novel diabetes drugs in clinical management: Extending the opportunities
10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe - Online CME
Early intervention for lifetime CV risk reduction
10' education - May 30, 2018 - Prof. John Deanfield, MD - London, UK - Online CME
Why cardiologists should be more interested in PAH
3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Mardi Gomberg-Maitland, Falls Church, VA, USA - Online CME
The future of renal denervation in the treatment of hypertension
3' education - Mar. 9, 2018 - VBWG at ACC, Orlando, FL, USA - Prof. Michael Böhm, Homburg, Germany
Emerging approaches to dyslipidemia management beyond LDL-c
3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA
Clinical trials in diabetes and CVD: What did we learn?
10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya - Online CME
How to manage DOAC-related bleeding
10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen
Statin-associated muscle symptoms: real or nocebo effect?
3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. Paul Thompson, Hartford, CT, USA
What are the key mechanisms of CV benefit of novel diabetes drugs?
10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar - Online CME
The ORBITA trial: is PCI beneficial in stable angina patients?
3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Prof. William Boden, Boston, MA, USA
Considerations on antithrombotic treatment of VTE and AF patients
10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen
New left ventricular assist device lowers stroke risk vs. gold standard
3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - James Januzzi - Boston, MA, USA
What is the science driving CVD and T2DM?
10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser - Online CME
Mutated bone marrow stem cells may link aging, cancer and atherosclerosis
3' education - Mar. 9, 2018 - ACC 2018, Orlando, FL, USA - Prof. Peter Libby, Boston, MA, USA
Dyslipidemia in diabetes patients
10' education - Apr. 10, 2018 - Prof. Kausik Ray - Imperial College London, UK
The CANTOS trial: Implications for the management of patients with residual risk
10' education - Nov. 16, 2017 - Prof. Paul Ridker - Boston, MA, USA - Online CME
Hypoglycemia in cardiovascular medicine: why worry?
10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME
Anti-inflammatory therapy in the prevention of cardiovascular disease
10' education - Nov. 16, 2017 - Prof. Peter Libby, USA
Key classes of antidiabetic drugs – How do they work?
10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME
Results of ODYSSEY OUTCOMES and FOURIER trials complement each other
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Steven Nissen, MD - Cleveland, OH, USA
Messages from the ODYSSEY OUTCOMES trial
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Prof. Kausik Ray, Imperial College Londen, UK
Reversal agent for FXa inhibitors is effective and safe in interim analysis of ANNEXA-4 trial
3' education - Mar. 11, 2018 - Prof. Stuart Connolly, Hamilton, ON, Canada
Treatment with statin before PCI intervention reduces MACE in patients with ACS
3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, VS - Otavio Berwanger - São Paulo, Brasil
Ticagrelor non-inferior to clopidogrel for bleedings in post-STEMI patients
3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - Otavio Berwanger - São Paulo, Brasil
Pharmacist intervention in black barbershop beats usual care at lowering BP
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Ronald Victor, MD - Los Angeles, CA, USA
No evidence that anti-inflammatory treatment prevents progression to T2DM in CANTOS trial
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Brendan Everett, MD - Boston, MA, USA
A threefold role of cardiologists as advocates for better cardiology care
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, VS - Mary Norine Walsh, MD - Indianapolis, IN, USA
Anti-inflammatory treatment also gives MACE reduction in high-risk patients with kidney disease
3' education - Mar. 12, 2018 - ACC 2018, Orlando, FL, USA - Dr. Paul Ridker - Boston, MA, USA
Giving NOAC treatment at myocardial injury after non-cardiac surgery lowers major vascular complications
3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL, USA - P.J. Devereaux - Hamilton, ON, Canada
Total mortality, but not sudden cardiac death, lower by wearable cardioverter-defibrillator in the immediate post-MI period with low EF
3' education - Mar. 11, 2018 - ACC 2018, Orlando, FL. USA - Jeffrey Olgin (San Francisco, CA, USA
Results with PCSK9 inhibitor in ODYSSEY OUTCOMES above expectations, mortality benefit included
3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL. USA - Prof. Wouter Jukema - LUMC, The Netherlands
Results ODYSSEY OUTCOMES study can change clinical practice for treatment of high-risk ACS patients
3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Dr. Valentin Fuster, New York, NY, USA
Very good benefit-to-risk profile with PCSK9 inhibitor in high risk ACS patients in ODYSSEY OUTCOMES trial
3' education - Mar. 10, 2018 - ACC 2018, Orlando, FL, USA - Prof. Gabriel Steg, Paris, France
Diabetes cardiovascular outcome trials
10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME
HbA1c in CVD
10' education - Feb. 14, 2018 - Prof Naveed Sattar, MD - University of Glasgow, United Kingdom - Online CME
Inflammation & CVD: Translating insights from vascular biology to the clinic
10' education - Nov. 16, 2017 - Prof. Peter Libby, USA - Online CME
Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment
10' education - Nov. 15, 2017
Natural history of DM: Focus on micro- and macrovascular complications
10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME
The new era of residual risk reduction
10' education - Nov. 16, 2017 - Prof. Erik Stroes - Amsterdam, The Netherlands - Online CME
The patient with inflammatory residual risk: Who is it?
10' education - Nov. 16, 2017 - Prof. Wolfgang Koenig - Munich, Germany - Online CME
Diabetic dyslipidemia and residual risk in the era of LDL control
10' education - Jan. 25, 2018 - Boston, MA, USA - Dr. Aruna Pradhan - Brigham & Women's Hospital, Boston, USA
Lipoprotein metabolism & CV risk: a long road from understanding to treatment
10' education - Jan. 6, 2017 - Prof. John JP Kastelein, Amsterdam, The Netherlands
Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?
10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA
REVEALing where we stand with HDL
10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Christopher Cannon - Brigham & Women's Hospital, Boston, USA
Lipid management in primary prevention: Challenges in the era of low LDL-c & novel therapies
10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Samia Mora - Brigham & Women's Hospital, Boston, MA, USA
Integrating anti-PCSK9 therapy into primary and secondary prevention of CVD
10' education - Oct. 26, 2017 - Boston, MA, USA - Prof. Deepak Bhatt - Brigham & Women's Hospital, Boston, MA, USA
Can LDL go too low? Lessons from 25 years of cholesterol lowering
10' education - Oct. 26, 2017 - Boston, MA, USA - Dr. Robert Giugliano - Brigham & Women's Hospital, Boston, USA
There is hope for treatment of HFpEF
3' education - Nov. 24, 2017 - WCN congress, Amsterdam, The Netherlands - Prof. Carolyn Lam, MD - Singapore
Staggering results for weight reduction in T2DM
3' education - Dec. 18, 2017 - IDF 2017 - Abu Dhabi, UAE - Prof Naveed Sattar, MD - Glasgow, UK
New therapeutic options can make a difference for diabetic patients with high CV risk
3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK
Novel insights in the management and prognosis of pulmonary hypertension
5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Prof Nazzareno Galiè - Bologna, Italy
Neurotoxin injection did not prevent the common complication of AF after cardiac surgery
3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA, USA - Nathan Waldron, MD - Durham, NC, USA.
New ACC/AHA hypertension guidelines empasize risk assessment
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA
A coordinated effort to organise STEMI care improved treatment time and patient outcomes
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - James Jollis, MD - Chapel Hill, NC, USA
Positive lesson from a negative trial comparing peri-operative continuation or interruption of DOAC therapy
3' education - Nov. 15, 2017 - AHA 2017 - Anaheim, CA - David H. Birnie, MD - Ottawa, ON, Canada
Machine learning program predicts that drinking more coffee lowers risk of CVD and stroke
3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Laura M Stevens - Aurora, CO, USA
Highly adhering to a plant-based diet is associated with a lower risk of developing HF
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA
Sodium Bicarbonate and N-Acetylcysteine tested for the prevention of serious adverse outcomes
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - AHA 2017 - Anaheim, CA, USA
Good BP measurement depends more on appropriate technique than on absence of staff
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Karen Johnson - Memphis, TN, USA
Target for BP lowering differs between Europe and USA
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Prof. Clyde Yancy - Chicago, IL, USA
Restrictive transfusion is non-inferior to liberal approach during cardiac surgery
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - David Mazer - Toronto, Ont, Canada
Analogous to LDL-c, the lower the better also seems true for inflammation
3' education - Nov. 14, 2017 - Paul Ridker, Boston, MA, USA
Clinical outcomes and adverse effects comparable across various BP measurement methods in SPRINT
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Dr. Sripal Bangalore - NYU Langone, New York, NY, USA.
New ACC/AHA Hypertension Guidelines: stress on accuracy BP measurement method and lifestyle changes ánd a new target
3' education - Nov. 14, 2017 - AHA 2017 - Anaheim, CA - Paul Whelton, MD (Tulane University, New Orleans, LA, USA
More insight into effects of treatment with PCSK9 inhibition from 5 new FOURIER analyses
3' education - Nov. 14, 2017 - Anaheim, CA, USA - Robert Giugliano - Boston, MA, USA
Robust benefits for CV and limb event risk in PAD patients on PCSK9 inhibition
3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Bonaca - Boston, MA, USA
Greater relative and absolute risk reduction in high-risk subgroup with previous MI treated with PCSK9 inhibition
3' education - Nov. 13, 2017 - AHA 2017 - Anaheim, CA - Marc Sabatine - Boston, MA, VS
PCSK9 inhibition & CV events: Review of recent and upcoming hard endpoint outcome trials
10' education - Aug. 26, 2017 - Barcelona, Spain - Peter Sever, MD London, United Kingdom - PACE-CME symposium at ESC 2017 - Online CME
Ultime notizie sulla terapia: Un farmaco anti-infiammatorio riduce eventi cardiovascolari maggiori
5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Breakthrough therapy: Anti-inflammatory drug can affect important CV outcomes
5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Cardiovascular protection in type 2 diabetes
5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden
Clinical implications of inhibiting inflammation as risk factor for progression of CVD
5' education - Aug. 27, 2017
Interleukin-1 Beta-Inhibition nach akutem Koronarsyndrom – ein neuer therapeutischer Ansatz
5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
Insights from the first trials in epigenetics in human: What is the way forward?
10' education - Oct. 20, 2017 - Barcelona, Spain - Stephen Nicholls, MD, Adelaide, Australia - PACE-CME symposium at ESC 2017 - Online CME
Heart failure & Diabetes: Time for a more unified approach
10' education - Oct. 19, 2017 - Barcelona, Spain - Stefan D. Anker MD, Berlin, Germany - PACE-CME symposium held at ESC 2017 - Online CME
Brief update on the LEADER cardiovascular outcomes trial
10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK
BP lowering with endovascular baroreflex amplification in resistant hypertension: the CALM-FIM study
3' education - Aug. 29, 2017 - Dr. Wilko Spiering - UMCU
Treatment of patients on oral anticoagulation who present with ACS
10' education - Sep. 15, 2017 - Dr. Jur ten Berg - Cardiologist, Nieuwegein, The Netherlands
Proof-of-Concept Studie: Zusätzliche therapeutische Strategie neben der Lipidsenkung reduziert das kardiovaskuläre Risiko
5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Proof-of-concept trial may provide additional treatment option beyond lipid lowering for CV risk reduction
5' education - Sep. 29, 2017 - ESC 2017, Barcelona, Spain
Promise of epigenetic modulation as a target in atherosclerotic patients
10' education - Aug. 26, 2017 - Barcelona, Spain - Erik SG Stroes, MD, Amsterdam, the Netherlands - PACE-CME symposium at ESC 2017 - Online CME
Management of CV Risk & T2DM: Implications of novel outcome trials
10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017 - Online CME
Take home messages of the ESC congress for better hypertension treatment
3' education - Aug. 29, 2017 - Dr. Clyde Jancy - Northwestern University, Feinberg University, Chicago, IL, VS
Una nueva era para la prevención cardiovascular: anti-inflamatorios además de la reducción lípidica.
5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain - Lina Badimon
A new era of CV prevention: Anti-inflammatory drugs on top of lipid lowering
10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain
PCSK9 inhibition across a wide spectrum of patients: One size fits all?
10' education - Aug. 26, 2017 - Barcelona, Spain - G. Kees Hovingh, MD, AMC, Amsterdam, The Netherlands - PACE-CME symposium at ESC 2017 - Online CME
MRA treatment early after STEMI may give mortality benefit
3' education - Aug. 30, 2017
A new challenge for precision medicine: selecting major contributing risk factors
5' education - Aug. 27, 2017 - ESC 2017, Barcelona, Spain
The Clinical Unmet need in the patient with Diabetes and ACS
10' education - Aug. 26, 2017 - Barcelona, Spain - Kausik Ray, MD Imperial College London United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME
Dopo 23 anni, lo studio CANTOS confermi l'ipotesi sull'infiammazione
5' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain
After 23 years, CANTOS trial shows that inflammatory hypothesis is right
10' education - Aug. 29, 2017 - ESC 2017, Barcelona, Spain
Diverse study data confirm the rationale of intensive lipid-lowering
3' education - Aug. 29, 2017 - Christie Ballantyne - Houston, Texas, VS
Imaging components of plaque not more informative than burden of plaque
3' education - Aug. 30, 2017 - Stephen Nicholls, MD, Adelaide, Australia
SGLT2 inhibition in cardiology: What a cardiologist needs to know
10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017 - Online CME
Understanding new PCSK9 outcome data: From the LDL-C hypothesis to LDL-c causality
10' education - Aug. 26, 2017 - ESC 2017, Barcelona, Spain - John Chapman, PhD, Paris, France - PACE-CME symposium - Online CME
The journey from vascular biology to the clinic: reducing inflammation lowers CV risk
10' education - Aug. 28, 2017
Well-conducted trial confirms principle that renal denervation can lower blood pressure
3' education - Aug. 29, 2017
First time CV reduction is achieved with CETP inhibition
3' education - Aug. 29, 2017
Large population study underscores that 'all in moderation' is still good nutrition advice
3' education - Aug. 29, 2017
Higher event risk with DAPT with potent P2Y12-antagonist than with clopidogrel-based treatment
3' education - Aug. 29, 2017
Achieving very low LDL-c levels (<0.5 mmol/L or <20 mg/dL) with PCSK9 inhibition is safe and effective
3' education - Aug. 28, 2017
Natural randomisation shows that mode of LDL-lowering determines CV benefit
3' education - Aug. 28, 2017
LDL-c still reduced after 1 year with siRNA against PCSK9
3' education - Aug. 28, 2017
NSAID ibuprofen increases blood pressure significantly more than other selective COX2 inhibitors
3' education - Aug. 28, 2017
Decades of science on the inflammatory hypothesis of atherosclerosis translate into actionable clinical therapeutic to reduce residual CV risk
3' education - Aug. 27, 2017
NOAC plus aspirin combination therapy better than aspirin alone to reduce CV events in CAD and PAD
3' education - Aug. 27, 2017
Lowering inflammation without affecting LDL-c benefits aggressively treated CV patients
3' education - Aug. 27, 2017
HDL: moving forward after disappointing results with HDL-mimetic in CARAT study.
10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia
BET inhibition in renal and cardiovascular disease: What is the clinical roadmap?
10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Kamyar Kalantar-Zade, MD UC Irvine School of Medicine Irvine, Ca, USA
Molecular mechanisms involved in the beneficial effect of BET inhibition in experimental renal disease
10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Marta Ruiz-Ortega – Fundación Jiménez Díaz, Madrid, Spain
The high risk diabetes patient: What is the need for novel approaches to reduce cardiovascular and renal risk?
10' education - June 5, 2017 - ERA-EDTA, Madrid Spain - Luis M Ruilope, MD – Hospital 12 de Octubre, Madrid, Spain
UK: Clinical Dialogues: Lipids & Diabetes 2017
3' education - July 7, 2017 - Stratford Upon Avon, United Kingdom - Prof Peter Sever
PCSK9 inhibition works, but you can’t force biology
10' education - Mar. 17, 2017 - Prof. Wouter Jukema – Leiden University Medical Center, The Netherlands - ACC 2017, Washington DC, USA
Identification of patients who will benefit is important after FOURIER
10' education - Mar. 19, 2017 - Prof. Ulf Landmesser - Charité - Universitätsmedizin Berlin, Germany - ACC 2017, Washington DC, USA
Landmark study with PCSK9 inhibitor will change clinical practice
10' education - Mar. 18, 2017 - Prof. Eric Bruckert - Pitié-Salpêtrière Hospital, Paris, France - ACC 2017, Washington DC, USA
Nanotherapeutic solutions to reduce atherosclerotic processes in the blood vessel
3' education - Mar. 16, 2017 - VBWG - ACC 2017 - John Cooke, MD, PhD - Houston, TX, USA
How incretin therapy changes diabetes and prediabetes management
3' education - May 22, 2017
HIV as a model to study effect of chronic inflammation on CV risk
3' education - Mar. 16, 2017 - VBWG ACC 2017
Lowering inflammation to address residual CV risk
3' education - Mar. 17, 2017 - Dr. Paul M. Ridker - Boston, MA, USA
Type of glycemic control is more important than tight glycemic control
3' education - May 1, 2017 - ESC HF 2017, Paris
Changing therapeutic behaviour after FOURIER
10' education - Mar. 18, 2017 - Prof. Wolfgang Koenig - Munich, Germany - ACC 2017, Washington DC, USA
Step forward in telemonitoring through use of an algorithm that risk-stratifies HF patients
3' education - May 31, 2017 - ESC HF 2017, Paris
Emerging therapeutic areas in lipid management and CV disease
3' education - Mar. 16, 2017 - VBWG - ACC 2017 - Sotirios Tsimikas - La Jolla, CA, USA
Disappointing results with therapy for acute heart failure
3' education - Apr. 30, 2017 - ESC HF 2017, Paris
Initiating digoxin in AF patients associated with early hazard of sudden death
3' education - Mar. 19, 2017 - ACC 2017, Washington, DC, USA - Dr. Renato Lopes
Challenges in Heart Failure management: Diabetes and Renal Impairment
10' education - May 12, 2017 - Paris, France - Martin Cowie, MD - ESC Heart Failure, Paris
The implications of PCSK9 outcome trials for GPs
10' education - Mar. 19, 2017 - Prof. Richard Hobbs – Oxford, United Kingdom - ACC 2017, Washington DC, USA
SGLT2 inhibition & Heart Failure: Lessons from EMPA REG Outcome
10' education - May 9, 2017 - Paris, France - Per-Henrik Groop, MD - ESC Heart Failure, Paris
PCI-registry-based trial shows that IFR is non-inferior to FFR, with reduced discomfort and stenting
3' education - Mar. 20, 2017 - Matthias Götberg - Lund University, Sweden
Factor Xa inhibitor vs. aspirin in extended phase of prevention recurrent VTE
3' education - Mar. 18, 2017 - ACC 2017, Washington, DC, USA - Dr. Philip S. Wells - Ottawa, ON, Canada
New diabetes drugs and heart failure: What have we learnt?
10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris
E-counselling improves adherence in hypertensives
3' education - Mar. 21, 2017 - Dr. Rob Nolan, Toronto, ONT, Canada
PCSK9 inhibitors: From bench to bedside
10' education - Mar. 17, 2017 - Prof. Gilles Lambert – Sainte-Clotilde, France - ACC 2017, Washington DC, USA
Troponin is an independent predictor of CV events at non-cardiac surgery
3' education - Mar. 21, 2017 - Dr. P.J. Devereaux - Hamilton, ONT, Canada
New diabetes treatments with CV benefit: A changing role for the cardiologist
3' education - Apr. 19, 2017 - Robert J Chilton, MD (San Antonio, TX, USA)
The longer you treat, the better the benefit: lessons from PCSK9 inhibitors trials
10' education - Mar. 19, 2017 - Prof. Stephen J. Nicholls - Adelaide, Australia - ACC 2017, Washington DC, USA
Lowering LDL-c for a longer period of time really matters
10' education - Mar. 17, 2017 - Paul M. Ridker - Boston, MA, USA - ACC 2017, Washington DC, USA
No J-shaped curve for efficacy in PCSK9 outcome trials
10' education - Mar. 18, 2017 - Prof. Kausik Ray - London, United Kingdom - ACC 2017, Washington DC, USA
PCSK9 outcome trials: The results put into perspective of other clinical developments
10' education - Mar. 19, 2017 - Prof. Peter Sever - London, United Kingdom - ACC 2017, Washington DC, USA
LDL lowering for CVD prevention: From hypothesis to axiom
10' education - Mar. 19, 2017 - Prof. John JP Kastelein - Amsterdam, The Netherlands - ACC 2017, Washington DC, USA
Implications PCSK9 Outcome Trials: Should LDL-c targets in high-risk individuals be maintained or further lowered?
10' education - Mar. 18, 2017 - Prof. John Chapman - Paris, France - ACC 2017, Washington DC, USA
PCSK9 inhibitor safe for cognitive function, even at very low cholesterol levels
3' education - Mar. 19, 2017
Humanised PCSK9 antibody lowers CV events in high-risk patients, but LDL-c lowering effects decline over time
3' education - Mar. 17, 2017
CV outcomes with a PCSK9 inhibitor: FOURIER study
3' education - Mar. 16, 2017
Get involved in May Measurement Month!
3' education - Jan. 22, 2017 - London, United Kingdom - Prof. Neil R Poulter, MD (London, UK) - ISH President
Tailoring oral anticoagulation in elderly patients with AF
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Christopher B. Granger, MD (Durham, NC, USA)
How low to go with blood pressure: J-curve or not?
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Deepak L.Bhatt, MD, MPH (Boston, MA, USA)
Shifting priorities of care for older cardiac patients
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Daniel E. Forman, MD (Pittsburgh, PA, USA)
HFpEF in older adults: TTR amyloid, under diagnosed and treatable?
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Mathew S. Maurer, MD (New York, NY, USA)
Advancing CV care of cancer patients: Where are we now?
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Javid J. Moslehi, MD (Nashville, TN, USA)
Modifying CV risk by managing diabetes
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
Blood pressure control in CKD in older people
3' education - Nov. 12, 2016 - New Orleans, LA, USA - Prof. George L Bakris, MD (Chicago, IL, USA)
What is the underlying pathophysiology of PAH and what are its characteristics?
3' education - Jan. 11, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
Which clinical PH groups can be distinguished?
3' education - Jan. 10, 2017 - Bologna, Italy - Prof Nazzareno Galiè
How common is PAH and what are its risk factors?
3' education - Jan. 9, 2017 - Bologna, Italy - Prof Nazzareno Galiè - Online CME
How is PAH diagnosed?
3' education - Jan. 8, 2017 - Bologna, Italy - Prof Nazzareno Galiè - Online CME
How can PAH patients be functionally classified
3' education - Jan. 7, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
How is the prognosis of PAH established?
3' education - Jan. 6, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
Which treatment options can be pursued and which drugs are approved for PAH?
3' education - Jan. 5, 2017 - Bologna, Italy - Prof Nazzareno Galiè - Online CME
Careful implementation of PCSK9 inhibitors in clinical practice
10' education - Aug. 30, 2016 - ESC Rome, Italy - Prof. dr. Terje Pedersen (Oslo, Norway)
A minority of FH patients is identified and labeled as such, which impacts treatment
10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Kausik Ray, MD (London, UK)
Promising results in pivotal trials of novel lipid-modifying drugs
3' education - Dec. 12, 2016 - Amsterdam, The Netherlands - Prof. John JP Kastelein, MD (AMC Amsterdam, The Netherlands)
How do we follow-up PAH patients non-responsive to therapy and how can therapy be optimized?
3' education - Jan. 10, 2017 - Bologna, Italy - Nazzareno Galiè, MD - Online CME
Investigational epigenetic therapy lowers incidence of MACE in phase 2b study
3' education - Nov. 15, 2016 - AHA 2016, New Orleans, LA, USA - Dr. Norman Wong, Calgary, AB, Canada
No clinical benefit of potent P2Y12 inhibitor over clopidogrel in peripheral artery disease
3' education - Jan. 4, 2017 - AHA 2016, New Orleans, LA, USA - Prof. Freek Verheugt, Amsterdam, The Netherlands
CAC reveals evidence of coronary artery calcification in third of low-risk women
3' education - Nov. 14, 2016 - AHA, New Orleans, LA, USA - Dr. Maryam Kavousi, Rotterdam, The Netherlands
Possible approaches in precision medicine for secundary CV prevention
10' education - Aug. 30, 2016 - ESC Rome, Italy - Dr. Noel Bairey Merz (Los Angeles, CA, USA)
Would lower than the current ApoB targets be more useful for clinical decision-making?
10' education - Aug. 29, 2016 - ESC Rome, Italy - Seth Shay Martin, MD (Baltimore, MD, VS) and Allan Sniderman, MD (Montreal, Quebec, Canada).
Bisphosphonate as a potential new treatment for CV risk reduction
10' education - Aug. 27, 2016 - ESC, Rome, Italy - Guido Kranenberg (Utrecht, The Netherlands)
Emerging therapies and treatment strategies in pulmonary arterial hypertension
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul R. Forfia, MD - Philadelphia, PA, USA
Outstanding questions and ongoing studies on the use of NOACs
3' education - Oct. 7, 2016 - Berg en Dal, The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA)
Oral anticoagulation in daily clinical practice in varous patient populations
10' education - Oct. 6, 2016 - The Netherlands - Prof. Chris Granger, MD (Durham, NC, USA) and Marc Brouwer, MD (Nijmegen, The Netherlands)
Understanding why patients do not take their medication and stimulating adherence
10' education - Aug. 27, 2016 - ESC Rome, Italy - Prof. Robert Horne (London, United Kingdom)
Lipid-lowering in the elderly - considering net benefit
3' education - Nov. 22, 2016 - AHA 2016 - Neil J. Stone, MD (Northwestern University Feinberg School of Medicine, Chicago, IL, USA)
Peak VO2 maintained in HF patients on IV iron therapy
3' education - Nov. 22, 2016 - AHA 2016 - Dirk Jan van Veldhuisen, MD (UMC Groningen, The Netherlands)
New class of lipid-lowering medication shows lasting LDL-c lowering in dose-finding study
3' education - Nov. 22, 2016 - Kausik Ray, MD - Imperial College London, United Kingdom
Brief update on various pharmacotherapeutic strategies to lower CV risk
3' education - Nov. 21, 2016 - AHA 2016 - Prof. Wouter Jukema, MD (LUMC Leiden, The Netherlands)
PCSK9 inhibitor on top of statin therapy gives additional atheroma volume regression
3' education - Nov. 21, 2016 - AHA 2016 - Steve Nissen, MD (Cleveland Clinic, Cleveland, OH, USA)
Iron deficiency in the new HF guidelines
3' education - Aug. 29, 2016 - Peter van der Meer, MD - University Medical Center Groningen, The Netherlands
What can new glucose-lowering SGLT2-inhibitors add to CV risk management in diabetes?
10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Silvio E Inzucchi (New Haven, CT, USA)
Extra work of checking device data weekly does not translate into benefit for HF patient
3' education - Oct. 25, 2016 - ESC - 2016 Rome - Martin Cowie, MD - National Heart & Lung Institute, London, UK
Customising therapy approach in ACS based on underlying pathology seems promising
3' education - Oct. 21, 2016 - ESC - 2016 Rome - Ik-Kyung Jang, MD - Massachusetts General Hospital, Boston, MA, USA
Interim results of new device for treatment resistant hypertension
10' education - Aug. 29, 2016 - ESC Rome, Italy - Dr. Wilko Spiering (Utrecht, The Netherlands)
Targeting residual inflammatory risk as a strategy to lower CV risk
10' education - Aug. 29, 2016 - ESC Rome, Italy - Prof. Paul Ridker (Boston, MA, USA)
Heart failure news at the ESC
10' education - Aug. 29, 2016 - ESC - 2016 Rome - Frank Ruschitzka, MD - University Heart Center, Zurich, Switzerland
No added value of monitoring platelet function after ACS
3' education - Oct. 6, 2016 - ESC - 2016 Rome - Stefan Gielen, MD - University of Leipzig, Germany
No indication for difference in efficacy between potent platelet inhibitors after PCI
3' education - Aug. 30, 2016 - ESC - 2016 Rome - Steen Dalby Kristensen, MD - Aarhus University, Denmark
CPAP treatment of OSA neutral on CV endpoints but beneficial for quality of life
3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Doug McEvoy, MD (Adelaide Institute for Sleep Health, Flinders University, Adelaide, Australia)
Frequency apheresis lowered in FH patient receiving PCSK9-inhibiting treatment
3' education - Oct. 4, 2016 - ESC - 2016 Rome - Prof Patrick M Moriarty, MD (University of Kansas Medical Center, KS, USA)
To SPRINT or not to SPRINT to a lower blood pressure target?
10' education - Aug. 29, 2016 - ESC Rome, Italy - William C Cushman (Memphis, TN, USA) and Sverre E Kjeldsen (Oslo, Norway)
Novel strategies targeting residual risk: The promise of PCSK9 inhibiting therapies
10' education - Aug. 28, 2016 - ESC 2016, Rome - Erik Stroes, MD – Academic Medical Center, Amsterdam, The Netherlands - PACE-CME symposium held at ESC 2016 in Rome
Beyond statins: The role of ezetimibe in targeting residual risk
10' education - Aug. 29, 2016 - ESC 2016, Rome - Chris Packard, MD – University of Glasgow, United Kingdom
Inflammation as potential target for therapy to target residual risk post ACS
10' education - Aug. 27, 2016 - ESC 2016, Rome - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
Mendelian randomisation study suggests that CV prevention could be simpler and more effective
3' education - Sep. 21, 2016 - ESC - 2016 Rome - Dr. Brian Ference (Detroit, MI, VS)
Heart Failure news from ESC 2016 at a glance
3' education - Sep. 21, 2016 - ESC - 2016 Rome - Prof. Mariell Jessup (Philadelphia, PA, USA)
A clinical perspective on PCSK9 inhibition: What do we know an what can we expect?
10' education - Aug. 27, 2016 - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA
PCSK9, the short track road from discovery as drug target towards the clinic
10' education - Aug. 27, 2016 - ESC 2016, Rome - Gilles Lambert, MD – Université de la Réunion, Sainte-Clotilde, France
Role of PCSK9 in the regulation of LDL cholesterol
Sep. 12, 2016
LDL cholesterol, the LDL receptor pathway & PCSK9
Sep. 10, 2016
Surviving elevated Lp(a): a patient story from diagnosis to treatment
10' education - May 27, 2016 - Innsbruck, Germany - Sandra Revill Tremulis, MBA - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
A patient with elevated Lp(a): What is current clinical practice to manage this condition?
10' education - May 27, 2016 - Innsbruck, Germany - Prof. Klaus G. Parhofer, MD - University of Munich, Germany - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
The future perspectives for care for patients with high Lp(a)
10' education - May 27, 2016 - Innsbruck, Germany - Prof. Erik Stroes, MD PhD – Academic Medical Center, Amsterdam, The Netherlands - FRIDAY, MAY 27, 2016, lunch symposium at Lp(a) symposium prior to EAS
Epigenetics: A closer look at BET inhibition
Sep. 5, 2016
HF & Diabetes: SGLT2 inhibition a paradigm shift?
10' education - Aug. 29, 2016 - ESC 2016, Rome, Italy - John McMurray, MD University of Glasgow United Kingdom - Recorded at PACE-CME symposium held during ESC 2016 in Rome
Challenging cardiovascular risk in diabetes: ready for a new approach?
10' education - Aug. 29, 2016 - John Deanfield, MD, University College London, United Kingdom
Overview of SGLT-2 inhibitors in T2DM management: current position & future promise
10' education - Aug. 29, 2016 - ESC, Rome Italy - Silvio Inzucchi, MD, Yale Diabetes Center, New Haven, CT, USA - PACE-CME symposium held at ESC 2016, Rome
Understanding BET inhibition as a novel pathway for cardiovascular risk modulation
10' education - Aug. 28, 2016 - ESC 2016, Rome - Jorge Plutzky, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA - Recorded at PACE-CME symposium at ESC 2016
BET inhibition in cardiovascular disease: A new dawn?
10' education - Aug. 28, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands - Recorded at PACE-CME symposium at ESC 2016
The high risk diabetes patient with cardiovascular disease: What else can we target to reduce cardiovascular risk?
10' education - Aug. 28, 2016 - ESC 2016, Rome - Kausik Ray, MD – Imperial College London, United Kingdom - Recorded at PACE-CME symposium at ESC 2016
Preparing for a novel era in CV prevention: Where do PCSK9 inhibitors fit in lipid management?
10' education - Aug. 27, 2016 - ESC 2016, Rome - John Kastelein, MD – Academic Medical Center, Amsterdam, The Netherlands
The effect of treatment with DPP-4 inhibition on renal complications in diabetic patients.
3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
A changing treatment paradigm in diabetes
3' education - July 30, 2016 - Bangkok, Thailand - Richard E. Pratley, MD (Florida Hospital Diabetes Institute, Orlando, FL, USA)
SGLT2 inhibition in diabetic kidney disease
3' education - Aug. 24, 2016 - Bangkok, Thailand - Prof. Per-Henrik Groop (University of Helsinki, Finland)
New agents to treat hyperkalaemia
3' education - July 18, 2016 - ACC 2016 - Bertram Pitt, MD
Exciting times in diabetes treatment: new drug class moves beyond glucose reduction
3' education - Apr. 23, 2016 - Kuala Lumpur - Naveed Sattar - University of Glasgow, United Kingdom
Inflammation, the immune system and atherosclerosis
10' education - July 7, 2015 - Amsterdam IAS
The future of HF management: How does potassium binding fit within pharmacological treatment of heart failure?
10' education - June 28, 2016 - ESC HF 2016, Florence, Italy - Kenneth Dickstein, MD - University of Bergen Stavanger University Hospital, Norway
Heart failure and SGLT2 inhibition: understanding the mechanism for potential benefit
10' education - May 21, 2016 - ESC HF 2016, Florence, Italië - Naveed Sattar, MD - Glasgow Universtiy, Glasgow, UK
Hyperkalemia: Novel treatment strategies to manage potassium levels in heart failure
10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Peter van der Meer, MD - UMCG Groningen, The Netherlands
RAAS inhibition in heart failure: Corner stone of therapy & potassium homeostasis
10' education - May 23, 2016 - ESC HF 2016, Florence, Italy - Faiez Zannad, MD - CHU- Nancy University Nancy, France
SGLT2 inhibition and cardiovascular outcomes: lessons from recent clinical trials
10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - David Fitchett, MD - University of Toronto, ONT, Canada
Current treatment of Diabetes in Heart Failure
10' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors, MD - UMCG Groningen, The Netherlands
Novel small molecule that inhibits PAI-1 in development to slow vascular aging
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Douglas E. Vaughan, MD - Chicago, IL, USA
Two additions to the therapeutic armory to treat HFrEF
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Scott D. Solomon, MD - Boston, MA, USA
Inadequate anticoagulant treatment for stroke prevention in atrial fibrillation
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Christian T. Ruff, MD - Boston, MA, USA
How to treat residual inflammatory risk?
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Paul Ridker, MD - Boston, MA, USA
Evolving hypotheses on the mechanisms underlying ACS
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter Libby, MD - Boston, MA, USA
New therapies for type 2 diabetes show CV benefit beyond their glucose-lowering effect
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Silvio E. Inzucchi, MD - New Haven, CT, USA
Elucidating the role of gut microbes in CVD may provide future therapeutic strategies
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Stanley L. Hazen, MD, PhD - Cleveland, OH, USA
Steps forward in lipid-lowering therapy
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Robert P. Giugliano, MD - Boston, MA, USA
Managing cardiorenal syndrome in the context of heart failure
3' education - Apr. 1, 2016 - VBWG Meeting at ACC 2016, Chicago, IL, USA - Peter A. McCullough, MD - Dallas, TX, USA
HOPE-3 trial suggests that statin therapy is beneficial even in low-risk populations
3' education - May 16, 2016 - Dubai, United Arab Emirates - Kausik Ray, MD (Imperial College, London, UK)
Statin lowers CV risk, in absence of LDL-c measurement
3' education - Apr. 28, 2016 - ACC 2016, Chicago - Jackie Bosch (Hamilton, ONT, Canada)
New 2016 ESC Heart Failure Guidelines
3' education - May 21, 2016 - ESC HF 2016, Florence, Italy - Adriaan Voors (Groningen, The Netherlands)
BP-lowering medication should not be used in normotensive primary prevention population at intermediate CV risk
10' education - May 10, 2016 - ACC 2016, Chicago, IL, USA - Eva Lonn (Hamilton, ONT, Canada)
The spectrum of Heart Failure
10' education - May 11, 2016 - Boston, MA, USA - Dr. Marc Pfeffer
The EMPA REG Outcome trial: The challenge for cardiologists in managing T2DM
3' education - May 10, 2016 - David Fitchett, MD, University of Toronto, Canad
CV protection by SGLT2 inhibition: Potential mechanisms for benefit
3' education - May 10, 2016 - Kuala Lumpur, Malaysia - Prof Hiddo Lambers Heerspink, Groningen, The Netherlands
Review of cardiovascular safety of DPP4 inhibitors
3' education - May 6, 2016 - Dubai, UAE - Dr Sanjay Rajagopalan, MD, Maryland
Stroke reduction with PPAR-Y antagonist pioglitazone
3' education - May 6, 2016 - Dubai, UAE - Dr Robert J Chilton
No benefit of direct renin inhibition in HF in ATMOSPHERE trial
3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Lars Køber
Recommendations on novel treatments should be composed sooner after publication of evidence
3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Milton Packer
What surprises have emerged from genetic studies of coronary artery disease?
10' education - Apr. 25, 2016 - Boston, MA, USA - Dr. Sekar Kathiresan (Boston, MA, USA)
CV benefit of daily statin therapy in the HOPE-3 trial
3' education - Apr. 18, 2016 - ACC 2016, Chicago, IL, USA - Jackie Bosch
Attenuating inflammation by inhibition of p38 MAP-kinase does not reduce CV endpoints in LATITUDE TIMI-60
3' education - Apr. 11, 2016 - ACC 2016, Chicago, IL, USA - Michelle O'Donoghue
GAUSS-3: Statin intolerance a real problem and PCSK9 inhibition with evolocumab effective
3' education - Apr. 3, 2016 - ACC 2016, Chicago - Steven L Nissen
HOPE-3: Statin therapy works in everybody with intermediate-risk
3' education - Apr. 8, 2016 - Salim Yusuf MD, McMaster University, Hamilton, Ontario
ACCELERATE: No reduction of major CV events with CETP inhibition
3' education - Apr. 7, 2016 - ACC, Chicago 2016 - Stephen J. Nicholls, MD, PhD
Diabetic dyslipidaemia and residual risk in the era of LDL control
10' education - Mar. 21, 2016 - Boston, MA, USA - Aruna Pradhan
How will anti-PCSK9 therapy integrate into primary and secondary prevention of CVD?
10' education - Mar. 16, 2016 - Boston, MA, USA - Prof. Deepak Bhatt
Recent advances in lowering CV risk with antidiabetic agents
3' education - Feb. 12, 2016 - Boston, MA, USA - Prof Stephen Wiviott
Changing views on mechanisms of atherosclerosis
10' education - Feb. 12, 2016 - Boston, MA, USA - Prof. Peter Libby (Boston, MA, USA)
Inflammation and CV risk: Beyond statins in the treatment of atherosclerosis
3' education - Mar. 8, 2016 - Boston, MA, USA - Paul M Ridker
NOACs for Valve Disease?
3' education - Feb. 26, 2016 - VBWG Orlando - John Camm, London, UK
Impacting lipid disorders through personalised healthcare
3' education - Feb. 2, 2016 - VBWG, Orlando - Daniel J. Rader, M.D.
CV outcomes with medicines to control glycemia: highlights from recently completed trials
3' education - Feb. 2, 2016 - VBWG, Orlando - Darren K. McGuire, MD
C-Reactive Protein, Inflammation and Atherosclerosis
Jan. 24, 2016
Integrating Big Data with evidence generation for precision medicine: implications for cardiovascular disease
3' education - Nov. 7, 2015 - VBWG, Orlando FL, USA - Elliott M. Antman
The mechanism of SGLT2 inhibition in glucose control
Nov. 24, 2015
HF Summit : innovation in clinical care in heart failure
10' education - Oct. 31, 2015 - Barcelona, Spain - Prof. Adriaan Voors and Prof. Martin Cowie
A multidisciplinary approach in heart failure management
10' education - Oct. 31, 2015 - Barcelona, Spain - Aldo Maggioni, TIny Jaarsma, Richard Hobbs and Josep Comin-Colet
Living with heart failure: A patient perspective
3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Nick Hartshorne-Evans
Diagnosing Heart Failure: How, where and who?
3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Prof. Burkert Pieske
Where are we with HF patients with AF?
3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Dipak Kotecha
Novel insights and innovations in targeting the neurohumoral system
3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Peter van der Meer
A global overview of key developments in Heart Failure: Where are we now?
3' education - Oct. 30, 2015 - HF Summit, Barcelona, Spain - Dr. Kenneth Dickstein
How to classify your HF patients? Understanding HFpEF versus HFrEF
3' education - Oct. 31, 2015 - HF Summit, Barcelona, Spain - Dr. Carolyn Lam
The advent of novel nonsteroidal mineralocorticoid receptor antagonists in heart failure
3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof Bertram Pitt
Antidiabetic therapy reduces CV mortality and HF outcomes in high-risk patients
3' education - Nov. 10, 2015 - AHA 2015, Orlando, FL, USA - Prof. Silvio Inzucchi
Major new phase in heart failure management
3' education - Nov. 9, 2015 - AHA 2015, Orlando, FL, USA - Milton Packer
Accumulating clinical data on PCSK9 inhibition: What are the key lessons?
10' education - Sep. 30, 2015 - ESC 2015 London - Paul M Ridker, MD – Brigham and Women’s Hospital, Harvard Medical School, Boston, USA
SGLT2 inhibitor outcome trials: Future opportunities
10' education - Sep. 27, 2015 - London - Dr David Fitchet, Toronto, Canada
SGLT2 inhibition in the management of type 2 diabetes: Potential impact on CVD Risk
10' education - Sep. 29, 2015
What is the story about Diabetes & CVD: Rationale for a multifactorial approach
10' education - Sep. 29, 2015
Diabetes & Cardiovascular Disease:The risk factor to be challenged
10' education - Sep. 27, 2015
Lipid Management 2020: A glance at the future
10' education - Sep. 24, 2015
Inflammation as target for therapy in atherothrombosis
10' education - Aug. 31, 2015 - ESC London - Prof Paul M Ridker
Inflammation and Thrombosis
10' education - Sep. 29, 2015
Inflammation in Acute Myocardial Infarction & Ventricular Remodelling
10' education - Oct. 21, 2015 - ESC 2015, London UK at Monday, August 31, 2015
PARAMETER: heart failure agent to treat hypertension
3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
PARAMETER: heart failure agent to treat hypertension
3' education - Sep. 1, 2015 - ESC - Londen 2015 - Bryan Williams
PATHWAY-2: which agent can best treat therapy resistant hypertension?
3' education - Aug. 31, 2015 - ESC - Londen 2015 - Bryan Williams
Pharmacodynamics of investigational pre-beta HDL-mimicking agent
3' education - May 24, 2015 - ISA2015, Amsterdam - Eralp Bellibas
Reassuring safety data with investigational lipid-modifying agent
3' education - May 24, 2015 - ISA2015, Amsterdam - David Kallend
The mechanism of SGLT2 inhibition in glucose control
3' education - July 24, 2015
Statins are enough for the prevention of CVD
3' education - May 24, 2015 - ISA2015, Amsterdam - Prof Kausik Ray
A new prediction tool to identify disease-causing mutations in familial hypercholesterolaemia
3' education - May 24, 2015 - ISA2015, Amsterdam - Joost Besseling
Studying the cardioprotective properties of the phosphatidylserine-component of HDL
3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Anatol Kontush
The changing character of atherosclerotic disease
3' education - May 24, 2015 - ISA2015, Amsterdam - Prof. Peter Libby
Patients confident to use injectable PCSK9-inhibitor via self-injection
3' education - May 25, 2015 - ISA2015, Amsterdam - Bertrand Cariou
FH: Call for investigators to get involved
3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Evan Stein
CETP-inhibitor reduces non-HDL-c and PCSK9 in animal model
3' education - May 24, 2015 - ISA2015, Amsterdam - Dr. Yanan Wang
Persistent lipid changes with long-term treatment with mipomersen
3' education - May 24, 2015 - ISA2015, Amsterdam - dr. Paul Barton Duell
Combined hyperlipidaemia
3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Rob Hegele
The effects of a PCSK9-inhibitor on various lipid fractions
3' education - May 24, 2015 - ISA2015, Amsterdam - Gisette Reyes-Soffer
Lipid Management: diagnostics and guidelines
3' education - May 24, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
Homozygous FH: treatment challenges
3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Frederick Raal
New, more potent chemical agent to lower triglyceride levels
3' education - May 24, 2015 - ISA2015, Amsterdam - Harold Bays
PCSK9-inhibitor less frequently administered may be effective treatment option
3' education - June 15, 2015 - ISA Amsterdam - Prof. Eli Roth
Large pooled analysis reveals no safety concerns with PCSK9-inhibitor
3' education - June 16, 2015 - ISA2015, Amsterdam - Jennifer Robinson
Ezetimibe does not disturb glycaemic control
3' education - June 16, 2015 - ISA2015, Amsterdam - Peter Toth
TAUSSIG: clinically relevant LDL-lowering in difficult to treat patients
3' education - June 15, 2015 - ISA2015, Amsterdam - Prof. Frederick Raal
How to manage statin-intolerant patients?
3' education - June 11, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof. Erik Stroes
Lipids: Who is at real high risk?
3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - Prof Kausik Ray
Screening for Familial Hypercholesterolaemia
3' education - May 23, 2015 - PACE Lipid Masterclass - Amsterdam, May 23 2015 - dr. Kees Hovingh
Cardiovascular Inflammation and Immunity in Atherosclerosis:
10' education - June 7, 2015 - Amsterdam
Lowering triglycerides while raising LDL-c: is this a problem?
3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Børge Nordestgaard
Increase in LDL may not always be associated with increase in CV risk
3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Allyson Morton
Collective amnesia on dietary fats and LDL-c
3' education - May 25, 2015 - ISA Amsterdam, May 25, 2015 - Prof. Martijn Katan
Strong reduction CV events in FH patients with ApoB-inhibitor
3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Paul Barton Duell
John Chapman awarded for research on cholesterol particles
3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Prof. John Chapman, Paris, France
Harry Davis awarded with first Endo Award for discovery of ezetimibe
3' education - May 24, 2015 - ISA Amsterdam, May 24, 2015 - Dr. Harry Davis
Unique Dutch collaborative effort to identify FH patients
3' education - Apr. 1, 2015 - Amersfoort, The Netherlands - Dr. Janneke Wittekoek
OSLER studies Compelling data on PCSK9 inhibition
3' education - Mar. 15, 2015 - ACC 2015, San Diego - Marc Sabatine, MD Boston
OSLER 1 & 2: Long term efficacy and safety outcomes PCSK9 inhibition
3' education - Mar. 16, 2015 - ACC 2015, San Diego - Prof.dr. John Kastelein
Critique on the new AHA / ACC guidelines for lipid management
10' education - Nov. 7, 2014 - Barcelona, ESC - Prof Kausik Ray, Imperial College London, United KIngdom
First European experience with human MTP-inhibitor in HoFH
10' education - Oct. 24, 2014
CV Risk Master Class Panama
10' education - Nov. 2, 2014
CVRM Moscow 2014
10' education - Sep. 27, 2014
Hypertriglyceridemia: New small-molecule based strategies
10' education - Oct. 1, 2014 - Barcelona - Christie Ballantyne MD
CVRM Shanghai 2014
10' education - Sep. 27, 2014
